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HIGHLIGHTS 
 
 Cannabis has less prominent effects in regular users compared to non-regular users 
 The behavioral and physiological effects of cannabis lessen over repeated exposure 
 The acute effects of cannabis are less prominent during Δ9-THC active maintenance 
 Cognitive function is the domain showing the highest degree of tolerance 
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 The acute intoxicating, psychotomimetic and cardiac effects show partial tolerance  
 
ABSTRACT 
 
Previous studies have reported conflicting results in terms of acute effects of cannabis 
in man. Independently of other factors, such discrepancy may be attributable to the different 
cannabis use history of study volunteers. It is thought that regular cannabis users may 
develop tolerance to the effects of acute cannabis administration. Here we systematically 
review all studies examining the effects of single or repeated cannabinoid administration in 
man as a function of previous cannabis exposure. Research evidence tends to suggest that the 
acute effects of single cannabinoid administration are less prominent in regular cannabis 
users compared to non-regular users. Studies of repeated cannabinoid administration more 
consistently suggest less prominent effects upon repeated exposure. Cognitive function is the 
domain showing the highest degree of tolerance, with some evidence of complete absence of 
acute effect (full tolerance). The acute intoxicating, psychotomimetic, and cardiac effects are 
also blunted upon regular exposure, but to a lesser extent (partial tolerance). Limited research 
also suggests development of tolerance to other behavioral, physiological, and neural effects 
of cannabis.   
 
Keywords: Cannabis; Delta-9-tetrahydrocannabinol; Tolerance; Health; Cannabinoid receptor 
type 1 
 
1. INTRODUCTION 
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Cannabis is the most widely used illicit drug all over the world. Population data suggests 
that approximately 200 million people use cannabis (National Academies of Sciences, 2017) 
and an estimated 13 million individuals have a Cannabis Use Disorder (CUD, DSM-5, 
American Psychiatric Association, 2013) (Degenhardt et al., 2013). The prevalence of 
cannabis use is expected to increase following the current trend to decriminalize or legalize 
its use for therapeutic and recreational purposes (Hall and Lynskey, 2016; Hasin et al., 2017). 
However, the safety of recreational use of cannabis has been questioned by numerous 
epidemiological and clinical studies which have suggested an association between acute and 
chronic cannabis use on one hand, and development of a CUD as well as a number of adverse 
effects on physical and mental health, cognition, and psychomotor function on the other 
(Batalla et al., 2014; Bhattacharyya et al., 2012a; Blest-Hopley et al., 2018; Ford et al., 2017; 
Hall, 2015; Schoeler et al., 2016). Consistently, acute administration of delta-9-
tetrahydrocannabinol (∆9-THC), the main psychoactive ingredient of the Cannabis sativa 
plant, has been shown to induce physiological and psychiatric symptoms as well as 
neurocognitive and motor impairments (Batalla et al., 2014; Bhattacharyya et al., 2017; 
Bhattacharyya et al., 2015; Colizzi and Bhattacharyya, 2017; Curran et al., 2002; D'Souza et 
al., 2004; Ramaekers et al., 2006). Therefore, the effects of cannabis on cognition and health 
remain an important public health concern, especially in light of regulatory trends worldwide.    
To date, most experimental studies investigating the acute effects of cannabis or ∆9-
THC have been conducted in otherwise healthy cannabis users with a relatively low average 
frequency of lifetime cannabis use. However, using different methodologies, a number of 
studies have provided evidence that tolerance may develop to most of the subjective and 
behavioral effects of cannabis. In particular, studies conducted in the last decade have 
indicated that a single acute administration of ∆9-THC induce less pronounced subjective, 
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cognitive, behavioral, electrophysiological, neurochemical, and neuroendocrine effects in 
frequent cannabis users compared to occasional users (Cortes-Briones et al., 2015; D'Souza et 
al., 2008a; D'Souza et al., 2012; D'Souza et al., 2009; D'Souza et al., 2008b; Ramaekers et al., 
2009; Ranganathan et al., 2009; Schoeler and Bhattacharyya, 2013). Also, early studies have 
suggested that repeated cannabis administration reduces the subjective and physiological 
responses to re-challenge with cannabis (Haney et al., 1999; Kirk and de Wit, 1999; Nowlan 
and Cohen, 1977).  
Development of tolerance might explain why some studies conducted only in frequent 
cannabis users failed to show a clear effect of acute cannabis administration on cognitive 
performance (Hart et al., 2010; Hart et al., 2001; Ramaekers et al., 2011). Nevertheless, other 
similar studies indicate that frequent cannabis users report impairments in a broad range of 
cognitive domains upon acute ∆9-THC administration (Metrik et al., 2012; van Wel et al., 
2013). One potential explanation accounting for this discrepancy across studies could be that 
frequent cannabis users may not develop tolerance for every performance domain. Studies 
assessing a wider range of neuropsychological and physiological outcomes, only in frequent 
cannabis users (Hart et al., 2010) or in comparison to occasional users (Ramaekers et al., 
2009), suggest the development of tolerance to the effects of ∆9-THC on certain cognitive 
indices but not on psychomotor function, subjective-effect ratings, and physiological 
measures. Therefore, the role of previous cannabis exposure as a predictor of blunted 
response to cannabis intoxication is still debated. Understanding this appears also to be 
relevant to public policy debates regarding reform of laws related to cannabis use. For 
instance, in light of the potential development of tolerance to the acute effects of cannabis 
among regular users, some concern has been raised about the imposition of criminal liability 
for drivers who test positive for ∆9-THC without additional demonstrable evidence of 
psychomotor impairment (Armentano, 2013). 
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The purpose of this review is to summarize all available data generated by studies that 
have investigated development of tolerance to the acute effects of cannabis and/ or Δ9-THC 
in man by carrying out a systematic literature search for all such data. 
 
1.1. Objectives  
Our main objective was to carry out a systematic review of all available literature 
concerning the development of tolerance to the effects of cannabis and Δ9-THC in humans. 
Our aim was twofold: 1) To review which domains show tolerance upon repeated cannabis 
administration; 2) To review the extent to which tolerance develops for these domains. 
 
2. METHODS  
 
2.1. Inclusion/exclusion criteria 
In order to summarize previous literature investigating the development of tolerance 
to the effects of cannabis and Δ9-THC in man, inclusion criteria for studies were: (1) human 
studies, (2) studies investigating the impact of a single administration of Δ9-THC or cannabis 
in 2 or more populations with different levels of previous cannabis exposure (i.e. frequent 
users, occasional users, naïve individuals), (3) studies investigating the impact of a single 
administration of Δ9-THC or cannabis in a single population with variation in the extent of 
previous cannabis exposure (i.e. correlating the acute effect of Δ9-THC or cannabis on the 
outcome measure with the extent of previous cannabis exposure), or (4) studies investigating 
the impact of repeated administration of Δ9-THC or cannabis in population(s) of cannabis 
users (i.e. (re)assessing the outcome measure after every administration). In order to offer a 
comprehensive evaluation of the association between cannabis use and development of 
tolerance, a wide range of different outcome measures that have been reported in the 
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literature were considered, including, but not limited to, questionnaire data, laboratory tests, 
performance, physiological and neurobiological measures. Exclusion criteria were (1) studies 
where the effects of Δ9-THC or cannabis were not investigated under experimental 
conditions, (2) studies in which groups were not differentiated in terms of previous cannabis 
exposure, (3) studies which primarily assessed the effects of psychoactive substances other 
than cannabis, and (4) studies which primarily/ exclusively assessed cannabinoid 
pharmacokinetics without investigating other outcomes of interest.  
 
2.2. Search Strategy 
A literature search was performed using electronic databases (MEDLINE, Web of 
Science and Scopus) for any published original English-language research, using a 
combination of search terms describing cannabis (“marijuana”, “cannabis”, “THC/ delta-9-
tetrahydrocannabinol/ dronabinol”), its pattern of use (“heavy”, “regular”, “frequent”, “light”, 
“non-regular”, “occasional”), the study design (“acute”, “challenge”, “administration”),  and 
the outcome of interest (“tolerance”, “sensitization”), with a first search done on December 
21, 2017, and a final search done on June 18, 2018. Reference lists of eligible studies were 
also screened to identify additional relevant studies. 
 
2.3. Risk of bias 
Risk of bias and quality assessment of the methodologically heterogeneous group of 
studies reviewed here (Table 1) required a suitably inclusive and flexible approach. For this 
purpose, an adapted set of criteria suggested by the Agency for Healthcare Research and 
Quality (AHRQ) guidance (West et al., 2002), amended as appropriate for interventional 
studies in humans was used (Table 2). Risk of systematic bias across human studies was 
further identified by assessing all papers for possible confounding factors such as mental 
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health comorbidity, tobacco, alcohol, and other substance use among study samples (Table 
2).  
 
2.4. Calculation of the degree of tolerance development 
Whenever possible, development of tolerance was calculated in terms of percentage 
reduction. In light of methodological heterogeneity across studies (Table 1), a flexible 
approach was required to calculate this percentage according to the study design. In 
principle, the effect of cannabis during the “tolerance phase” (or in regular users as the 
“tolerant group”) was subtracted from the effect of cannabis during the “non-tolerance 
phase” (or in non-regular users as the “non-tolerant group”), divided by the reference value 
(pre-drug value; non-regular users placebo value; “non-tolerance phase” placebo value), and 
multiplied by 100. Further information on how the percentage was calculated for each 
specific study is reported in the Supplementary Methods. 
 
3. RESULTS 
 
3.1. Evidence at a glance 
 A number of studies have assessed the effects of Δ9-THC administration on 
subjective experiences, task performance on various cognitive and motor tasks, and 
physiological measures in volunteers with a previous history of frequent (Hart et al., 2010; 
Hart et al., 2001; Metrik et al., 2012; Ramaekers et al., 2011; van Wel et al., 2013) or 
occasional (Curran et al., 2002; Ramaekers et al., 2006) cannabis exposure, and have reported 
conflicting results. Some studies tend to confirm that the impairing effects of Δ9-THC 
observed in occasional cannabis users (Curran et al., 2002; Ramaekers et al., 2006) are absent 
in frequent cannabis users (Hart et al., 2001; Ramaekers et al., 2011). In contrast, other 
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evidence from similar studies suggests that frequent cannabis users are still sensitive to the 
detrimental effects of Δ9-THC (Metrik et al., 2012; van Wel et al., 2013) or develop selective 
tolerance, i.e., showing tolerance to the cognitive effects of Δ9-THC while still remaining 
sensitive to its subjective and physiological effects (Hart et al., 2010).  
In total 1252 records were identified. All abstracts of the records were screened 
against the inclusion and exclusion criteria (Figure 1). A final list of 36 studies reporting on a 
total of 1047 study participants (male = 782, female = 225; not specified = 40; Table 1) were 
identified which specifically investigated in otherwise healthy cannabis users whether 
tolerance develops to the acute effects of cannabis. These studies have used different 
experimental designs and studied heterogeneous populations. Further information on 
methodological quality of studies is reported in Table 2. These studies investigated whether 
the acute effects of cannabis vary: (i) between groups with different levels of previous 
cannabis exposure; (ii) within a group of individuals with different levels of previous 
cannabis exposure; (iii) upon repeated exposure; and (iv) upon concomitant treatment 
(‘maintenance’) with Δ9-THC. For the purpose of this review, in order to have a consistent 
nomenclature across studies, groups of “frequent” or “heavy” cannabis users were subsumed 
under the “regular” cannabis user group (RU). Similarly, groups of “infrequent” or 
“occasional” cannabis users were considered as “non-regular” cannabis users (NRU; Table 
2). In general, RU had: (i) a pattern of daily or weekly cannabis use; (ii) a history of recent 
cannabis use and/ or a urine drug screen (UDS) positive for cannabis at the time of the study; 
and (iii) a diagnosis of Cannabis Use Disorder and/ or a history of chronic exposure lifetime 
(often ≥ 100 times). Conversely, NRU had: (i) a pattern of weekly cannabis use or less; (ii) a 
negative history of recent cannabis use and/ or a urine drug screen (UDS) negative for 
cannabis at the time of the study; and (iii) a history of lifetime occasional or experimental 
exposure (often from < 5 to 100 times). 
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The most commonly investigated domains were subjective effects and intoxication, cognitive 
function, psychopathology, cardiac function, and pharmacokinetics. Other behavioral 
parameters less frequently studied involved food intake, social behavior, sleep quality, and 
driving skills. Finally, a number of studies investigated other physiological and 
neurophysiological parameters, including neurochemical, electrophysiological, and 
laboratory markers (Table 3). 
 
3.2. Intoxication and other subjective effects 
Intoxication and other subjective effects represent the outcome measure most 
commonly investigated in studies of tolerance to the effects of cannabinoids, with 22 studies 
conducted over the last 50 years. Single administration of marijuana cigarettes and/ or 
intravenous ∆9-THC didn’t induce different levels of intoxication in regular users (RU) and 
non-regular users (NRU) in four studies (Bosker et al., 2012; D'Souza et al., 2012; D'Souza et 
al., 2008b; Lindgren et al., 1981) [N (M ± SD, range): RU = 11.7 ± 2.6, 9-14; NRU = 11 ± 
1.7, 9-12]. Conversely, marijuana administration produced less pronounced and shorter 
intoxication in RU compared to NRU in 3 other studies conducted in larger samples (Lex et 
al., 1984; Ponto et al., 2004 (degree of tolerance observed: “High”, 89.5%; Cohen's d: 0.98); 
Fabritius et al., 2013) [N (M ± SD, range): RU = 14.7 ± 7.4, 9-23; NRU = 19.7 ± 8.4, 10-25]. 
Studies of repeated ∆9-THC or cannabis administration have more consistently demonstrated 
the development of tolerance to its intoxicating effects. In 1975, the first study with this 
experimental design comparing intoxication between RU and NRU indicated a trend level 
decrease in subjective intoxication upon continued marijuana exposure only in RU (Babor et 
al., 1975). A similar study involving repeated administration of ∆9-THC and crude cannabis 
extract in RU indicated a significant decrease in self-reported intoxication and sedation over 
the study period, but no significant changes in other subjective reports such as “Good 
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feelings” and “Withdrawal” (Jones et al., 1976 (degree of tolerance observed: “Sedation”, 
267.5%)). Other studies indicated that repeated ∆9-THC administration in RU result in a 
significant decrease in intoxication as well as other subjective effects (e.g. ratings of “Good 
drug effect” and “Stimulated”) (Gorelick et al., 2013 (degree of tolerance observed: “Good 
drug effect”, 633.3%; “High”, 276.5%); Haney et al., 1999) including ratings of strength, 
liking, and willingness to take the dose again (Haney et al., 1999). Another study indicated 
that intoxication reduces upon repeated marijuana administration in cannabis users, showing 
partial recovery after 1 week of abstinence (Nowlan and Cohen, 1977), with intoxicating 
effects fading away more rapidly in RU with a heavier pattern of cannabis use compared to 
other groups with light to moderate cannabis use (Nowlan and Cohen, 1977). Interestingly, 
three studies found that 10-15 min of marijuana smoking was sufficient to detect tolerance to 
the intoxicating effects of ∆9-THC, with RU showing less intoxication than NRU 
(Ramaekers et al., 2009; Theunissen et al., 2012 (degree of tolerance observed: “High”, 
29.1%); Desrosiers et al., 2015). Similarly, 2-3 min of vaporized cannabis induced less 
intoxicating effects with increasing frequency of past cannabis use (Ramaekers et al., 2016). 
Finally, a study comparing different routes of administration indicated that oral cannabis 
elicit intoxicating and subjective effects only in NRU, whereas vaporization and smoking had 
similar effects in RU and NRU. Also, “Good drug effect” and “Stoned” effect were higher 
under vaporized cannabis compared to oral cannabis only in RU (Newmeyer et al., 2017a 
(degree of tolerance observed: “Good drug effect”, 245.4%; “Stoned”, 1166.7%)). 
Meyer et al. reported a number of subjective experiences acutely induced by 
marijuana smoking, including changes in feeling, thinking, bodily sensation, perception, and 
general awareness. However, there was no difference between the responses of RU and NRU 
(Meyer et al., 1971). In other studies, RU didn’t show any significant change in identical 
(Bedi et al., 2010) or comparable (Vandrey et al., 2013) subjective measures upon repeated 
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∆9-THC administration. Kirk and De Wit found that NRU report greater sedative effects than 
RU at higher ∆9-THC doses, also reporting less stimulant and liking effects compared to a 
lower dose. Interestingly, the lower dose increased ratings of “Feel drug,” and “High” only in 
RU (Kirk and de Wit, 1999). Another study indicated attenuated marijuana-induced 
subjective effects during active maintenance with ∆9-THC in RU (Hart et al., 2002). 
 
3.3. Cognitive function 
Sixteen studies were identified specifically investigating the development of tolerance 
to the cognitive effects experienced upon acute intoxication with cannabis. The first study 
was performed in 1971 by Meyer et al. who compared the effect of marijuana smoking on 
several cognitive domains in RU and NRU. Upon acute intoxication, only NRU showed 
impairment in sustained attention. In contrast, groups did not differ significantly in their 
psychomotor ability, time sense, distractibility, and hand-eye coordination, even though 
impairments in these cognitive domains were evident to a greater extent in NRU than RU 
(Meyer et al., 1971). A more recent study indicated that the detrimental effects of marijuana 
smoking on divided attention are specific to NRU (Theunissen et al., 2012 (degree of 
tolerance observed: “DAT hits”, 9.8%)). Similar findings on attention were reported in 
another study which compared NRU and non-users (NU), wherein they reported that upon 
acute intoxication NRU were less impaired than NU while performing a divided attention 
task (Marks and MacAvoy, 1989).  
A second study investigating psychomotor ability with the same task used by Meyer 
et al (Meyer et al., 1971), the Digit-Symbol Substitution Test (DSST), indicated a dose-
dependent detrimental effect of ∆9-THC administration on this cognitive domain and 
confirmed that the decrease in performance doesn’t differ between RU and NRU (Kirk and de 
Wit, 1999). However, in recent years Ramaekers et al. have indicated that ∆9-THC marijuana 
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smoking impairs psychomotor ability, divided attention, and motor impulsivity in NRU, 
while impairing only motor impulsivity in RU at high ∆9-THC concentrations (Ramaekers et 
al., 2009), suggesting that RU develop tolerance also to the effect of ∆9-THC on 
psychomotor ability (Ramaekers et al., 2009). It is worth mentioning that this study used a 
different task, the Critical Tracking Test (CTT), which specifically assesses psychomotor 
coordination rather than a wider range of psychomotor functions at the same time as for the 
DSST (Jongen et al., 2015). Similar findings were reported in 2015 by Desrosiers et al. who 
showed that the ∆9-THC marijuana impairs CTT psychomotor ability and divided attention 
more prominently in NRU than RU, also increasing the number of tracking errors and false 
alarms as well as prolonging reaction times during divided attention only in NRU (Desrosiers 
et al., 2015). However, RU and NRU didn’t differ in terms of working memory or risk-taking 
and impulsivity (Desrosiers et al., 2015). Another study by Ramaekers and colleagues 
confirmed that ∆9-THC-induced CTT psychomotor ability impairment decreases with 
increasing frequency of past cannabis use, while ∆9-THC effects on executive function, 
impulse control, and divided attention are not affected by previous cannabis use (Ramaekers 
et al., 2016). Interestingly, in 2002 Hart et al. showed that marijuana smoking doesn’t 
markedly impair DSST psychomotor performance in RU during active maintenance with ∆9-
THC. Also, while acutely intoxicated with marijuana, RU performed better during active 
maintenance at the higher ∆9-THC dose compared to the lower dose or placebo (Hart et al., 
2002). 
A study in 1974 investigated the effect of marijuana smoking on verbal learning, 
indicating that RU performed similarly on a paired associate task whether intoxicated or not, 
while NRU tended to have a worse performance under the effect of marijuana (Cohen and 
Rickles, 1974). Also, NRU tended to perform better than RU under placebo, but worse under 
the effect of marijuana (Cohen and Rickles, 1974 (degree of tolerance observed: “Learning”, 
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82.1%)). In more recent years, a number of studies conducted by D’Souza and colleagues 
confirmed and extended these findings. In particular, intravenous administration of ∆9-THC 
appeared to impair immediate and delayed free recall at a verbal learning task more markedly 
(D'Souza et al., 2008b) or only (D'Souza et al., 2008a) in NRU compared to RU, despite 
worse baseline performance in RU compared to NRU (D'Souza et al., 2008b). Interestingly, 
during the delayed recall RU performed significantly better under ∆9-THC than placebo 
(D'Souza et al., 2008b). Also, detrimental effects of acute ∆9-THC challenge on spatial 
working memory were more prominent in NRU than RU (D'Souza et al., 2008a; D'Souza et 
al., 2009). However, these studies found that sustained attention performance during a 
Continuous Performance Task didn’t differ between RU and NRU (D'Souza et al., 2008a; 
D'Souza et al., 2008b). Along with previous evidence of absent or less marked impairment in 
divided attention with increasing frequency of past cannabis use (Desrosiers et al., 2015; 
Marks and MacAvoy, 1989; Ramaekers et al., 2009; Theunissen et al., 2012), these studies 
suggest selective development of tolerance for the effects of cannabis on divided attention but 
not on sustained attention. 
A single study specifically assessed the effect of intravenous administration of ∆9-
THC on time perception, indicating that ∆9-THC transiently impairs time estimation and 
production (Sewell et al., 2013). However, RU experienced less temporal distortion from ∆9-
THC than NRU (Sewell et al., 2013; degree of tolerance observed: “Time estimation”, 
11.2%; “Time production”, 8.9%). 
Studies of repeated ∆9-THC or cannabis administration have more consistently 
demonstrated the development of tolerance to its impairing effects on cognition. In 1976, an 
early study of repeated administration of ∆9-THC and cannabis crude extract in RU indicated 
that the ability to visually track a moving target and to perform cognitive and psychomotor 
tasks shows initial impairments and then returns to baseline or even better than pre-drug 
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performance levels, despite continuous drug administration (Jones et al., 1976). Another 
study indicated relatively minor disruptive effects of repeated ∆9-THC administration in RU 
on a number of cognitive domains including learning, memory, vigilance, and psychomotor 
ability, despite 4 days of abstinence preceding the drug challenge (Haney et al., 1999) while a 
more recent study reported no significant effects of repeated dronabinol (synthetic form of 
∆9-THC) administration on similar cognitive tasks in RU (Bedi et al., 2010).  
 
3.4. Psychopathology 
 Tolerance to the psychopathological effects of cannabis has received relatively less 
attention compared to other outcome measures, with the majority of the studies conducted in 
recent years. In 2008 a study by D’Souza et al. indicated blunted perceptual alterations, 
psychotomimetic symptoms, and anxiety in RU compared to NRU following a single 
intravenous administration of ∆9-THC (D'Souza et al., 2008b). Using the same assessment 
instruments, similar findings indicating less pronounced perceptual alterations and 
psychotomimetic symptoms in RU compared to NRU (D'Souza et al., 2009) as well as in 
recent cannabis users compared to non-recent users (D'Souza et al., 2012) were reported by 
the same group in subsequent studies conducted in non-overlapping samples. Using a similar 
methodology, Barkus et al. replicated these findings in 2011, indicating that the higher the 
previous use of cannabis the lower is the induction of psychotomimetic symptoms following 
acute challenge with ∆9-THC (Barkus et al., 2011). Further evidence indicated less anxiety in 
RU than NRU following 10 min of marijuana smoking (Desrosiers et al., 2015). Other 
evidence indicated less intense (Fabritius et al., 2013) and shorter confusion (Lex et al., 1984; 
Fabritius et al., 2013) in RU compared to NRU following ∆9-THC marijuana smoking. 
Only three studies of repeated ∆9-THC or cannabis administration were identified 
which specifically investigated the development of tolerance to the psychoactive effects of 
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cannabis. These studies focused on mood changes and reported conflicting results. Meyer et 
al. in 1971 didn’t find any difference in mood states between RU and NRU after marijuana 
smoking, apart from the “vigor” factor. In particular, under marijuana RU tended to become 
more vigorous while NRU less vigorous (Meyer et al., 1971). However, Jones et al in 1976 
found that upon repeated administration of ∆9-THC and cannabis crude extract there is a 
progressive lessening of the intensity of the mood changes experienced while intoxicated 
(Jones et al., 1976 (degree of tolerance observed: “Anxiety”, 80%). This finding was not 
confirmed by a study of repeated ∆9-THC administration conducted in 2010, indicating 
sustained self-reported positive mood effects of ∆9-THC, which do not decrease over time 
(Bedi et al., 2010).  
 
3.5. Cardiac function 
 Cardiac parameters have been frequently investigated in studies of tolerance to the 
effects of cannabinoids. Meyer et al. indicated that about 1 hour after smoking marijuana RU 
had a lower pulse rate compared to NRU (Meyer et al., 1971). Four subsequent studies 
conducted in larger samples confirmed that after smoking marijuana tachycardia is lower or 
less prolonged in RU compared to NRU (Lex et al., 1984; Desrosiers et al., 2015; Ponto et 
al., 2004 (degree of tolerance observed: “Pulse rate”, 13.2%; Cohen's d: 0.79); Ramaekers et 
al., 2009) [N (M ± SD, range): RU = 10.6 ± 3.1, 6-14; NRU = 12.6 ± 6.8, 6-24]. However, 
three other studies involving single or limited exposure to ∆9-THC or marijuana didn’t 
replicate this finding (Kirk and de Wit, 1999; Lindgren et al., 1981; Renault et al., 1971) [N 
(M ± SD, range): RU = 8.7 ± 2.5, 6-11; NRU = 7.7 ± 3.2, 4-10]. Another study also indicated 
that oral cannabis-induced tachycardia occurs at higher ∆9-THC blood levels only in NRU 
(Newmeyer et al., 2017a). Three of these studies suggested no difference in the effects of 
cannabis on blood pressure between RU and NRU (Newmeyer et al., 2017a; Ponto et al., 
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2004; Ramaekers et al., 2009), while a fourth study indicated a blunted increase in systolic 
and diastolic blood pressure in RU compared to NRU (Desrosiers et al., 2015).  
Studies of repeated exposure to cannabis indicated that tachycardia lessens upon 
repeated administration of ∆9-THC or marijuana (Jones et al., 1976; Nowlan and Cohen, 
1977), cannabis-induced tachycardia is less pronounced during active maintenance with ∆9-
THC (Benowitz and Jones, 1975 (degree of tolerance observed: “Pulse rate”, 11.3%); Jones 
et al., 1976; Vandrey et al., 2013), and tolerance develops for the orthostatic but not supine 
hypotensive effects of ∆9-THC (Benowitz and Jones, 1975 (degree of tolerance observed: 
“Hypotension”, 44.8%); Jones et al., 1976). 
Another study suggested that the intensity of the marijuana-induced tachycardia doesn’t 
differ between RU and NRU, while the duration of the effect is shorter in RU (Babor et al., 
1975). Finally, only a study of repeated administration of ∆9-THC in a small sample of RU 
and over a short period failed to indicate less pronounced effects on pulse rate and blood 
pressure over time (Gorelick et al., 2013 (degree of tolerance observed: “Pulse rate”, 9.9%)). 
 
3.6. Pharmacokinetics 
 A number of studies in recent years have investigated the pharmacokinetics of ∆9-
THC and its major metabolites, with particular attention to cannabinoid plasma 
concentrations. ∆9-THC hydroxylation results in 11-hydroxy-delta-9-tetrahydrocannabinol 
(11-OH-THC) and further oxidation in 11-nor-9-carboxy-delta-9-tetrahydrocannabinol 
(THC-COOH), which may be glucuronidated to 11-nor-9-carboxy-delta-9-
tetrahydrocannabinol glucuronide (THCCOO-glucuronide) (Grotenhermen, 2003). Research 
evidence indicates that RU with a history of recent cannabis exposure (Fabritius et al., 2013) 
or after a brief period of abstinence of 24 hours (D'Souza et al., 2008b; Ranganathan et al., 
2009) have higher THC-COOH levels than NRU at baseline. However, consistent findings 
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suggest that after a single intravenous administration of ∆9-THC RU and NRU do not differ 
in terms of ∆9-THC (Barkus et al., 2011; D'Souza et al., 2008b; Ranganathan et al., 2009) 
and THC-COOH levels (D'Souza et al., 2008b; Ranganathan et al., 2009). Similarly, RU and 
NRU do not differ in ∆9-THC, 11-OH-THC, and THC-COOH levels after administration of 
vaporized ∆9-THC (Ramaekers et al., 2016). In contrast, other studies indicate that after both 
marijuana smoking (Desrosiers et al., 2015; Ramaekers et al., 2009; Theunissen et al., 2012; 
Fabritius et al., 2013) and oral ∆9-THC administration (Bosker et al., 2012) RU have higher 
∆9-THC, 11-OH-THC, and THC-COOH levels than NRU. However, after accounting for 
baseline levels, this difference remains significant only for some studies (Ponto et al., 2004) 
but not for others (Fabritius et al., 2013). A very recent study highlighted how differences in 
cannabinoid levels between RU and NRU may depend on the route of administration 
(Newmeyer et al., 2017a). In particular, this study indicated that, compared to vaporized ∆9-
THC, oral administration of ∆9-THC is associated with higher 11-OH-THC levels only in 
NRU. Also, the higher the ∆9-THC levels after oral dosing, the higher is the intoxication 
experienced by NRU (Newmeyer et al., 2017a). Finally, a study conducting multiple 
evaluations of cannabinoid concentrations in RU suggested that ∆9-THC and 11-OH-THC 
levels steadily increase over 6 days of repeated dronabinol administration (Gorelick et al., 
2013). 
 
3.7. Other behavioral measures 
Only a limited number of studies have focused on other behavioral effects of cannabis. A 
study of repeated dronabinol administration conducted in a small sample of RU indicated that 
∆9-THC increases caloric intake, satiety, sleep satisfaction and efficiency, food craving for 
proteins and fats, but that these effects were reduced or no longer distinguishable from 
placebo in the 2nd half of the study (Bedi et al., 2010; degree of tolerance observed: “Total 
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daily caloric intake”, 11.7%; “Sleep satisfaction”, 15%). Also, RU in this study reported 
increased hunger and craving for carbohydrates only in the 2nd half of the study, with no 
significant effect on social behavior (Bedi et al., 2010). However, other studies in larger 
samples indicated that no tolerance develops to the effect of ∆9-THC on food intake (Haney 
et al., 1999; Hart et al., 2002) or sleep quality (Hart et al., 2002) over a period of repeated ∆9-
THC administration (Haney et al., 1999) or during active maintenance with ∆9-THC (Hart et 
al., 2002). Also, one of these studies confirmed previous evidence that social behavior in RU 
doesn’t change upon repeated exposure to ∆9-THC (Haney et al., 1999). Other evidence  
indicated that after a single administration of oral ∆9-THC RU exhibited less impairment in 
their driving skills compared to NRU (Bosker et al., 2012) or their performance was not 
significantly impaired (Newmeyer et al., 2017b). 
 
3.8. Physiological and neurophysiological measures  
 A number of studies specifically investigated development of tolerance to the 
physiological (other than cardiac) and neurophysiological effects of cannabis. Jones et al. in 
1976 indicated that administration of ∆9-THC and crude cannabis extract induce several 
responses in RU which lessen in magnitude upon repeated exposure including body 
temperature increase, skin temperature decrease, salivary flow decrease, intraocular pressure 
decrease as well as EEG alpha slowing and auditory-evoked potential amplitude decreases 
(Jones et al., 1976). Instead, in this study no tolerance developed to the decrease in serum 
haematocrit, haemoglobin, bilirubin, and plasma testosterone induced by repeated exposure 
to ∆9-THC and cannabis crude extract (Jones et al., 1976). Four subsequent studies 
confirmed tolerance to the acute effect of intravenous ∆9-THC administration (Cortes-
Briones et al., 2015; D'Souza et al., 2012) or marijuana smoking (Böcker et al., 2010; 
Theunissen et al., 2012 (degree of tolerance observed: “P100 targets”, 6.7%)) on specific 
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electrophysiological measures in RU. In particular, while performing a task, RU showed 
reduced P300a peak latency (D'Souza et al., 2012), increased P100 amplitude (Theunissen et 
al., 2012), and lower inter-trial coherence and evoked power (Cortes-Briones et al., 2015) 
compared to NRU. 
Studies by D’Souza and colleagues indicated that a single intravenous administration 
of ∆9-THC induced an increase in cortisol (D'Souza et al., 2008b; Ranganathan et al., 2009) 
and brain-derived neurotrophic factor (D'Souza et al., 2009) which was less pronounced in 
RU compared to NRU. Other evidence from the same group indicated that prolactin levels 
were lower in RU compared to NRU both before (D'Souza et al., 2008a; D'Souza et al., 
2008b; Ranganathan et al., 2009) and after acute challenge with ∆9-THC (D'Souza et al., 
2008b; Ranganathan et al., 2009). A previous study conducted in a smaller sample 
(Mendelson et al., 1984) had reported that acute administration of cannabis compounds, 
either orally or via smoking, did not significantly affect plasma prolactin levels in both RU 
and NRU (Cohen's d: 0.26). 
Studies have also reported that marijuana smoking was associated with a reduction in 
breath-holding duration only in NRU (Farris and Metrik, 2016) while respiration rate and 
expired carbon monoxide did not differ between RU and NRU acutely exposed to ∆9-THC 
(Newmeyer et al., 2017a). Another study indicated that regional cerebral blood flow did not 
differ between RU and NRU after smoking marijuana (Ponto et al., 2004). Barkus et al. found 
that previous cannabis use did not modulate dopamine release following intravenous 
administration of ∆9-THC (Barkus et al., 2011). 
Repeated ∆9-THC exposure had no effect on body weight in a study (Bedi et al., 
2010). In contrast, repeated ∆9-THC exposure induced weight gain in a longer study, 
although no tolerance developed to weight gain over the study period (Jones et al., 1976). 
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4. DISCUSSION 
 
To our knowledge, this is the first systematic review of all human studies examining 
whether tolerance develops to the acute effects of cannabis or its main psychoactive 
ingredient, Δ9-THC. Previous human studies have reported conflicting results in terms of 
acute effects of cannabis, especially on cognitive function (Hart et al., 2001; Ramaekers et 
al., 2006). Some authors have suggested that the apparent discrepancy was attributable to the 
different Δ9-THC content of the preparations study volunteers have been exposed to 
(Ramaekers et al., 2006). Although it is plausible that higher Δ9-THC content preparations 
would have a greater detrimental effect on neuropsychological performance, in line with the 
warnings about the potential health risk of increasing cannabis potency (higher Δ9-THC 
content) (Freeman and Swift, 2016), factors other than Δ9-THC content have been suggested 
to account for the apparent discrepant findings across studies (Nordstrom and Hart, 2006). In 
particular, Nordstrom and Hart have highlighted the importance of taking into account the 
cannabis use history of study volunteers when drawing conclusions regarding the acute 
effects of cannabis in man (Nordstrom and Hart, 2006). Of course, the two explanations are 
not mutually exclusive, as it has been suggested that among cannabis-naïve individuals 
higher Δ9-THC content may increase the likelihood of adverse psychological effects, such as 
anxiety, depression and psychotic symptoms (Hall, 2009). It is also worth noting that 
differing individual sensitivity to the effects of Δ9-THC and cannabis (Bhattacharyya et al., 
2012b; Bhattacharyya et al., 2014) as well as previous exposure to different cannabis strains 
with varying ratio of different cannabinoids, with opposing effects (Bhattacharyya et al., 
2015; Bhattacharyya et al., 2010) may also underlie these discrepant findings. 
Overall, this review demonstrates that cannabis has less prominent or no effects on a 
number of behavioral and physiological measures in regular users (RU) compared to non-
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regular users (NRU). Also, the behavioral and physiological effects of cannabis lessen over 
repeated exposure and often become no longer distinguishable from placebo. Moreover, the 
acute effects of cannabis are less prominent during active maintenance with Δ9-THC. These 
effects are discussed in detail below. 
 
4.1. Studies of single ∆9-THC or cannabis administration 
Studies of acute cannabis-induced behavioral and physiological effects have differed 
widely in methodology, administering marijuana or Δ9-THC at differing doses, in various 
ways (e.g. in a cigarette to be smoked, as “brownie” to be eaten, as a preparation to be 
injected or inhaled) and assessing effects at varying time points post-administration. Also, 
they have investigated these effects in people with varying levels of previous cannabis use 
and potential tolerance to its effects, and who have used the drug more or less recently before 
testing. Thus, it is not surprising that such studies have often produced a mixed pattern of 
results. 
Studies of a single dose of ∆9-THC or cannabis included in this review have 
specifically investigated if their acute effects differ as a function of previous cannabis 
exposure. In some of the studies there was no evidence to support the development of 
tolerance to the intoxicating effects of the drug (Bosker et al., 2012; D'Souza et al., 2012; 
D'Souza et al., 2008b; Lindgren et al., 1981). However, these studies recruited relatively 
small samples (Bosker et al., 2012; D'Souza et al., 2012; Lindgren et al., 1981) and/ or non-
regular users (NRU) with a wide range of previous cannabis exposure (Bosker et al., 2012; 
D'Souza et al., 2012; D'Souza et al., 2008b). Studies conducted in larger samples and on 
individuals well differentiated in their pattern of regular or non-regular cannabis use found 
less pronounced and shorter intoxication in regular users (RU) compared to NRU (Lex et al., 
1984; Fabritius et al., 2013; Ponto et al., 2004). 
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Studies examining the effects of a single dose of ∆9-THC or cannabis on cognitive 
function reported less pronounced impairments as a function of previous cannabis exposure 
in the domains of divided but not sustained attention (Desrosiers et al., 2015; Marks and 
MacAvoy, 1989; Ramaekers et al., 2009; Theunissen et al., 2012), verbal memory (Cohen 
and Rickles, 1974; D'Souza et al., 2008a; D'Souza et al., 2008b), and time perception (Sewell 
et al., 2013). Less clear is the effect of previous cannabis use on psychomotor ability over 
time, with studies suggesting development of tolerance to the detrimental effect of cannabis 
on psychomotor coordination (Desrosiers et al., 2015; Hart et al., 2002; Ramaekers et al., 
2009; Ramaekers et al., 2016) but not on other psychomotor processes such as response 
speed, sustained attention, visual spatial skills and set shifting (Kirk and de Wit, 1999; Meyer 
et al., 1971). Also, two studies suggested that driving skills are less (Bosker et al., 2012) or 
not affected (Newmeyer et al., 2017b) in RU compared to NRU following a single oral dose 
of ∆9-THC. Finally, limited evidence suggests that tolerance doesn’t develop to the effects of 
cannabis on working memory, risk-taking, impulse control, and executive functioning 
(Desrosiers et al., 2015; Ramaekers et al., 2016). 
 Over the last 10 years, studies have consistently shown that following acute 
intravenous administration of ∆9-THC (D'Souza et al., 2012; D'Souza et al., 2009; D'Souza et 
al., 2008b) or marijuana smoking (Desrosiers et al., 2015; Fabritius et al., 2013; Lex et al., 
1984) the transient induction of perceptual alterations, psychotomimetic (D'Souza et al., 
2012; D'Souza et al., 2009; D'Souza et al., 2008b) and anxiety symptoms (Desrosiers et al., 
2015) as well as symptoms of confusion (Fabritius et al., 2013; Lex et al., 1984) is less 
pronounced in RU than NRU. Also, the more individuals have used cannabis in the past, the 
greater has been the tolerance to the acute psychotomimetic effects of ∆9-THC (Barkus et al., 
2011). 
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 Single or limited exposure to ∆9-THC or marijuana has been associated with lower 
tachycardia in RU compared to NRU in some (Desrosiers et al., 2015; Meyer et al., 1971; 
Ponto et al., 2004; Ramaekers et al., 2009; Lex et al., 1984) but not all studies (Kirk and de 
Wit, 1999; Lindgren et al., 1981; Renault et al., 1971). This discrepancy could be attributable 
to the low statistical power of studies failing to report development of tolerance to the 
cannabis-induced tachycardia. Also, limited evidence suggests that at higher ∆9-THC blood 
levels RU are more tolerant to the oral cannabis-associated tachycardia compared to NRU 
(Newmeyer et al., 2017a). Less clear is the effect on blood pressure, with only one 
(Desrosiers et al., 2015) out of four studies (Newmeyer et al., 2017a; Ponto et al., 2004; 
Ramaekers et al., 2009) suggesting a less prominent increase in systolic and diastolic blood 
pressure in RU compared to NRU.  
Other studies of single ∆9-THC administration or limited exposure to marijuana 
suggest that RU develop tolerance to the effect of cannabis on electrophysiological function 
(Cortes-Briones et al., 2015; D'Souza et al., 2012; Theunissen et al., 2012; Böcker et al., 
2010), cortisol (D'Souza et al., 2008b; Ranganathan et al., 2009), prolactin (D'Souza et al., 
2008a; D'Souza et al., 2008b; Ranganathan et al., 2009), Brain-derived neurotrophic factor 
(D'Souza et al., 2009), and breath-holding duration (Farris and Metrik, 2016). Instead, 
respiration rate (Newmeyer et al., 2017a), regional cerebral blood flow (Ponto et al., 2004), 
and dopamine release (Barkus et al., 2011) didn’t differ following acute administration of ∆9-
THC as a function of previous cannabis exposure. However, the study by Barkus et al. was 
conducted in a small sample and was not designed explicitly to test the development of 
tolerance as a function of previous cannabis exposure (Barkus et al., 2011). Therefore, 
whether tolerance develops to the potential ∆9-THC-induced acute release of dopamine 
remains unclear. 
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4.2. Studies of repeated ∆9-THC or cannabis administration 
For understandable reasons, monitoring the behavioral and physiological effects of 
∆9-THC or cannabis upon repeated administration represents the best suitable research 
paradigm to investigate development of tolerance. Consistently, there is much more 
agreement between studies of repeated ∆9-THC or cannabis administration compared to 
studies of single ∆9-THC or cannabis administration with reference to the association 
between cannabis use and tolerance development. In particular, all such studies have shown 
development of tolerance to the intoxicating effects of cannabis in RU compared to NRU 
upon continuous exposure (Babor et al., 1975; Gorelick et al., 2013; Haney et al., 1999; Jones 
et al., 1976). Also, the intoxicating effect of ∆9-THC is greater at higher ∆9-THC plasma 
concentrations only in NRU (Newmeyer et al., 2017a). In contrast, the greater the extent to 
which RU have used cannabis in the past, the faster has been the decline in the intoxicating 
effects of cannabis (Nowlan and Cohen, 1977). Tolerance to the intoxicating effects of 
cannabis has been reported with both marijuana smoking (Desrosiers et al., 2015; Ramaekers 
et al., 2009; Theunissen et al., 2012) and vaporized cannabis (Ramaekers et al., 2016). 
However, limited evidence suggests that RU may display greater tolerance to the intoxicating 
effects of cannabis when it is administered orally compared to the vaporized route of 
administration (Newmeyer et al., 2017a). 
Studies indicated relatively minor or no effects of repeated ∆9-THC administration in 
RU on a number of cognitive domains including learning, memory, vigilance, and 
psychomotor ability (Bedi et al., 2010; Haney et al., 1999; Jones et al., 1976). This absence of 
effect in RU might indicate the development of full tolerance. Intriguingly, tolerance to the 
cognitive effects of ∆9-THC was still evident even after a brief period of abstinence (Haney 
et al., 1999).  
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 Repeated ∆9-THC or cannabis administration has been shown to blunt the mood 
changes associated with use of the drug only in one (Jones et al., 1976) out of three studies 
(Bedi et al., 2010; Meyer et al., 1971). However, evidence is too limited to draw any 
conclusion. Further research is needed to investigate whether upon repeated cannabis 
exposure tolerance develops to cannabis-associated psychosis-like symptoms and anxiety.  
 All (Babor et al., 1975; Benowitz and Jones, 1975; Jones et al., 1976; Nowlan and 
Cohen, 1977; Vandrey et al., 2013) but one study conducted in a small sample and over a 
short follow-up period (Gorelick et al., 2013) indicated less pronounced effects of repeated 
administration of ∆9-THC or marijuana on tachycardia (Babor et al., 1975; Benowitz and 
Jones, 1975; Jones et al., 1976; Nowlan and Cohen, 1977; Vandrey et al., 2013), and 
orthostatic hypotension (Benowitz and Jones, 1975; Jones et al., 1976). Also, repeated ∆9-
THC administration has been associated with progressive tolerance to the effects of cannabis 
on body temperature, skin temperature, salivary flow, intraocular pressure, and 
electrophysiological function (Jones et al., 1976). Moreover, progressive tolerance has been 
shown to the effects of repeated ∆9-THC administration on food intake and sleep only in one 
(Bedi et al., 2010) out of three studies (Haney et al., 1999; Hart et al., 2002). Finally, other 
studies have indicated that repeated exposure to ∆9-THC has no effect on social behavior 
(Bedi et al., 2010; Haney et al., 1999) and body weight (Bedi et al., 2010) and no tolerance 
develops to its effects on haematocrit, haemoglobin, bilirubin, plasma testosterone, and body 
weight (Jones et al., 1976). 
 
4.3. Neurobiological mechanisms underlying development of tolerance 
Studies seem to indicate that after a brief period of abstinence of 24 hours, RU in the 
non-intoxicated state have higher levels of ∆9-THC metabolites compared to NRU (D'Souza 
et al., 2008b; Ranganathan et al., 2009). What is less clear is whether cannabinoid plasma 
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concentrations differ after acute administration of ∆9-THC depending on the extent of 
previous cannabis use (Fabritius et al., 2013), with some studies indicating higher levels of 
∆9-THC and its metabolites in RU compared to NRU (Bosker et al., 2012; Desrosiers et al., 
2014a; Desrosiers et al., 2015; Ramaekers et al., 2009; Theunissen et al., 2012), and other 
studies reporting no difference (Barkus et al., 2011; D'Souza et al., 2008b; Ramaekers et al., 
2016; Ranganathan et al., 2009). The discrepancy might be due to the different routes of ∆9-
THC administration used in these studies, with only oral and smoke routes leading to higher 
cannabinoids levels in RU compared to NRU (Bosker et al., 2012; Desrosiers et al., 2014a; 
Desrosiers et al., 2015; Ramaekers et al., 2009; Theunissen et al., 2012), and not intravenous 
or vaporized exposure (Barkus et al., 2011; D'Souza et al., 2008b; Ramaekers et al., 2016; 
Ranganathan et al., 2009). The potential higher cannabinoid levels in RU are not surprising 
given ∆9-THC highly lipophilic nature and extended excretion in chronic or frequent 
cannabis users (Desrosiers et al., 2014a).  
Some studies have indicated that the higher concentrations of ∆9-THC (Newmeyer et 
al., 2017c) and its metabolites (Fabritius et al., 2013) observed in RU compared to NRU 
following acute exposure were potentially due to the already higher cannabinoid levels in RU 
at baseline (Newmeyer et al., 2017c; Fabritius et al., 2013) and reflected recent exposure 
(Toennes et al., 2010). This was in line with evidence that ∆9-THC concentrations declined 
rapidly over the first few hours following cannabis use (Toennes et al., 2008; 2010). Also, the 
co-occurrence of higher concentrations of other cannabinoids in RU, such as cannabinol or 
cannabigerol (Sworwood et al., 2017), might be indicative of recent cannabis use independent 
of the experimental drug challenge (Newmeyer et al., 2016). Moreover, it has been suggested 
that the longer cannabinoid detection windows observed in RU compared to NRU following 
∆9-THC smoking (Desrosiers et al., 2014b; Anizan et al., 2013; Himes et al., 2013) might 
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suggest that RU smoked more efficiently (Toennes et al., 2008) rather than indicating 
significant changes in ∆9-THC pharmacokinetics. 
The question arising is whether the higher cannabinoid levels in RU may be at least in 
part a consequence of modified biotransformation activities and be ultimately accountable for 
the development of tolerance observed following repeated exposure. Limited preclinical 
evidence indicates that repeated exposure to synthetic cannabinoids leads to tolerance 
through an alteration of the drug metabolizing enzyme system (Costa et al., 1996). 
Conversely, a large body of research seems to indicate that tolerance may develop also in the 
absence of pharmacokinetic changes and be attributable to pharmacodynamic events such as 
cannabinoid receptor type 1 (CB1) down regulation, receptor conformational change, and 
receptor internalization, with a subsequent decreased interaction of ligand and receptor 
(Ameri, 1999). However, CB1 receptor downregulation and related desensitization varies in 
rate and magnitude across the brain. For instance, CB1 receptor downregulation has been 
observed in the striatum, cerebellum and limbic forebrain, but not in the ventral 
mesencephalon, and some areas such as the hippocampus show faster and greater CB1 
receptor downregulation and desensitization than other brain areas such as the basal ganglia 
(Ameri, 1999). In line with evidence from animal models (Rubino et al., 1997), this 
difference might explain why the development of tolerance follows different time courses and 
occurs to different extent in human studies reviewed here, with potential full tolerance 
developing for cognitive impairments whereas only partial tolerance develops for some 
physiological functions. For instance, regular users seem to show blunted responses to the 
amnestic but not to the euphoric effects of ∆9-THC, which may be mediated by different 
regions, the hippocampus and basal ganglia respectively (D'Souza et al., 2008b). Recent 
studies have indicated that RU may show blunted responses to the neurophysiological 
alterations induced by ∆9-THC in brain areas relevant to the manifestation of psychosis-like 
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symptoms as well as verbal memory, response inhibition, attentional salience, and emotional 
processing (Colizzi et al., 2018a, in press; Colizzi et al., 2018b, in press). 
 
4.4. Other substance use and tolerance 
 Psychostimulants such as cocaine and amphetamine induce a variety of behavioral 
and physiological effects, including psychoactive and cardiovascular effects as well as 
changes in appetite and body temperature (Kiyatkin, 2013; Frazer et al., 2018; Mladěnka et 
al., 2018). Preclinical evidence suggests that following sustained exposure to these drugs, 
tolerance develops for most of their effects (Zernig et al., 2007)). Similarly, evidence from 
human studies suggests that tolerance to cocaine (Mendelson et al., 1998) and 
methamphetamine (Strakowski et al., 2001) physiologic, neuroendocrine, and subjective 
effects may occur as a function of repeated exposure. Pharmacodynamic mechanisms have 
been suggested to explain the development of tolerance to the effects of psychostimulant 
drugs, such as alterations in dopamine release, uptake, transporter, and corresponding tone 
(Ferris et al., 2012). However, as for cannabis, although the accumulation from regular 
exposure might account for the higher plasma levels of cocaine and amphetamine observed in 
some experimental studies, the possibility of pharmacokinetic alterations cannot be ruled out 
(McMillan, 1991).  
Studies included in this review have tried to take into account the confounding effects 
of other psychostimulant use. However, the possible synergistic effects of cannabis and other 
psychostimulant drugs on tolerance development deserve further study. Preclinical studies 
have shown how repeated cannabinoid administration blunts the meso-accumbens dopamine 
response to an acute challenge with cannabinoid agonists but also to an acute challenge with 
cocaine and amphetamine, suggesting that tolerance to the effects of ∆9-THC may lead to 
cross-tolerance for the effects of other psychostimulant drugs (Pistis et al., 2004). 
AC
CE
PT
ED
 M
AN
US
CR
IPT
29 
 
 
4.5. Implications for psychosis and Cannabis Use Disorder 
What does this mean in terms of the development of a Cannabis Use Disorder (CUD) 
or psychosis in response to regular cannabis use? Development of tolerance to the 
intoxicating effects of cannabis, especially effects that are pleasurable, is consistent with a 
need to use progressively greater amounts of cannabis recreationally in order to get the same 
enjoyable effects, leading in turn to the development of a CUD. In those who end up 
developing a CUD but not a psychotic disorder, it is also likely that a similar progressive 
attenuation of the negative effects, in particular the psychotomimetic effects of cannabis 
would have occurred, thereby supporting continued use. This is consistent with a growing 
body of evidence that the risk of a CUD is higher among individuals experiencing early 
positive reactions to cannabis, possibly reflecting individual differences in the responsiveness 
of the mesolimbic dopamine system to the reinforcing effects of substance administration 
(Fergusson et al., 2003), while negative reactions are more likely to predict cessation of use 
(Sami et al., 2018). However, in those who end up developing a psychotic disorder or 
experiencing its relapse following continued cannabis use, independent, replicated evidence 
suggests that the risk of onset of psychosis (Colizzi and Murray, 2018; Moore et al., 2007; 
Sami and Bhattacharyya, 2018) or its relapse (Schoeler et al., 2016; Colizzi et al., 2016a) is 
linked to regular, frequent use, arguing against the development of tolerance to the 
psychotomimetic effects in these individuals. Whether this means that in such individuals, 
tolerance may selectively be developing to certain effects of cannabis and not to the 
psychotomimetic effects remains to be tested. Further studies are also needed to clarify 
potential biological differences between cannabis users who develop tolerance to the effects 
of the drug and cannabis users who develop psychotic or cannabis use disorders. The 
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possibility that cannabis users who develop tolerance to the acute psychotomimetic effects of 
∆9-THC are still at increased risk of psychosis cannot be ruled out. 
 
4.6. Methodological limitations 
Groups of regular (RU) and non-regular cannabis users (NRU) differed considerably 
across studies in terms of their pattern and frequency of cannabis use prior to assessment as 
well as dose and route of administration during the experiment (see methodological quality of 
studies in Table 2), limiting the comparison of the findings across the domains investigated. 
These aspects were partially mitigated in studies of repeated ∆9-THC or cannabis exposure, 
as the tolerance phenomenon was investigated in a controlled environment where subjects 
received standardized amounts of cannabis or its main active ingredient over a time period. 
Conversely, it represented a substantial limitation in studies of single ∆9-THC or cannabis 
exposure, where the tolerance manifestation, if present, followed a single administration and 
was modulated by previous cannabis exposure itself of study participants. This would explain 
the higher consistency and evidence of tolerance among studies of repeated ∆9-THC or 
cannabis exposure, potentially accounting for discrepancies among studies of single ∆9-THC 
or cannabis exposure. Independent of these explanations, differences in sample size across 
studies might also explain the inconsistent evidence for the development of tolerance to the 
intoxicating and cardiac effects of cannabis in studies of single ∆9-THC or cannabis 
exposure. The largest of these studies (Ponto et al., 2004) indicated tolerance development for 
both domains with a large effect size. However, the available data didn’t allow a systematic 
power calculation across studies. Moreover, very limited evidence seems to suggest that the 
development of tolerance differed according to the route of administration, with higher 
tolerance when cannabis is administered orally compared to other routes of administration 
(Newmeyer et al., 2017a). However, data was too limited to draw any conclusion.  
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Also, the large majority of the studies reviewed here recruited a group of RU 
presenting with recent cannabis use and often a urine drug screen positive for ∆9-THC, as 
this represented an inclusion criterion to differentiate participants with regular versus non-
regular cannabis use. Thus, as stated before, this limits the possibility of disentangling 
whether the higher levels of ∆9-THC and its metabolites observed among RU in some of 
these studies represent an alteration in pharmacokinetic processes such as distribution, 
metabolism and elimination, or just the consequence of ∆9-THC accumulation within the 
organism. Both phenomena may coexist, as indicated by cellular studies suggesting complex 
relationship between ∆9-THC accumulation and its metabolism in the brain (Monnet-Tschudi 
et al., 2008). Likewise, it is not clear whether tolerance to the effects of ∆9-THC would 
persist after an adequate period of abstinence. Limited evidence reviewed here suggests that 
RU are still tolerant to the cognitive effects of ∆9-THC on cognitive processes after 4 days of 
abstinence preceding the drug challenge (Haney et al., 1999). Also, other evidence suggests 
that tolerance to the intoxicating effects of cannabis upon repeated exposure shows only 
partial recovery after 1 week of abstinence (Nowlan and Cohen, 1977). However, despite 
being identified as a crucial pharmacodynamic mechanism underlying tolerance development 
following sustained cannabis exposure (Ameri, 1999), CB1 receptor downregulation has been 
shown to be selective and rapidly reversed after just two days of monitored abstinence from 
cannabis (D'Souza et al., 2016). Future studies need to examine whether tolerance persists 
after longer periods of abstinence preceding the acute challenge and its relationship with 
downregulation of CB1 receptor across different brain areas.  
An alternative explanation for the blunted effects of ∆9-THC in RU is that RU, 
especially when not developing psychosis-like symptoms, may be innately protected from 
some of the detrimental effects of cannabis. It has been shown that monozygotic twins are 
more likely to report similar experiences when exposed to cannabis compared to dizygotic 
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twins (Lyons et al., 1997). Also, inter-individual variation in the availability of cannabinoid 
receptors (Bhattacharyya et al., 2017) as well as genetic variation in cannabinoid (Colizzi et 
al., 2015a; Taurisano et al., 2016) and dopamine signalling (Bhattacharyya et al., 2014; 
Colizzi et al., 2015b; Colizzi et al., 2015c) have been linked to variation in the extent of 
psychotomimetic and neurocognitive effects of cannabis and ∆9-THC. However, the higher 
concordance within studies of repeated ∆9-THC or cannabis administration compared to 
studies of single ∆9-THC or cannabis administration in reporting an association between 
regular cannabis use and development of tolerance argues against the possibility that 
tolerance in RU may be explained by genetically determined differences. 
 
4.7. Future directions and conclusions 
Available evidence suggests that the effects of acute marijuana or Δ9-THC 
administration are less prominent in individuals with a regular pattern of cannabis use 
compared to non-regular users. Cognitive function appears to be the domain most likely to 
demonstrate tolerance upon repeated exposure, with some evidence of full tolerance 
indicating a complete absence of acute effect. The acute intoxicating and cardiac effects of 
Δ9-THC are also blunted upon regular exposure. Similar but limited evidence also suggests 
blunted acute psychotomimetic effects of Δ9-THC in individuals using cannabis regularly. 
The degree of tolerance in these domains varies, with generally an evidence of partial 
tolerance that is presence of some, albeit attenuated acute effects. Less clear or very limited is 
the evidence supporting the development of tolerance for other behavioral, physiological, and 
neural effects of cannabis.   
The adverse effects of repeated ∆9-THC administration on neurons may occur 
through a combination of pathways involving cannabinoid receptor activation (Colizzi et al., 
2016b), accumulation of cannabinoids and their metabolites, and upregulation of 
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neuroinflammatory cytokines (Monnet-Tschudi et al., 2008). Thus, tolerance may play a 
relevant role in the cascade of neurobiological events leading to disorders affecting brain 
chemistry and circuitry. Further studies are needed to better understand the neurobiological 
mechanisms underlying the development of tolerance upon repeated cannabis exposure in 
man.  
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Figure 1. PRISMA flowchart of search strategy for systematic review 
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Table 1. Summary of human studies investigating development of tolerance in cannabis users  
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Study Aim of study Population n Outcome measure (test name or description) Behavioral results Laboratory and physiological results 
Meyer et al., 
1971 
Effects of MJ on 
subjective effects, 
psychopathology, 
cognition, and cardiac 
parameters 
1. RU (n=6);  
2. NRU (n=6) 
12 Sympathetic arousal (Finger sweat), “psychedelic 
experience” (DEQ), dependence (Hidden patterns), 
attention (CPT), psychomotor ability (DSST), time 
sense (TPT), focus and distraction (SCWT), hand-eye 
coordination (Pursuit rotor), mood states (POMS), 
“High” (PR) 
1. Subjective effects, NS; 2. Mood states, NS (apart from 
“vigor” factor, RU > NRU); 3. Impaired attention, RU 
< NRU (MJ effect only in NRU); 4. Other cognitive 
performance, NS   
5. “High” by the end of experiment (PR at ~1h), 
RU < NRU 
Renault et 
al., 1971 
Effects of MJ on cardiac 
parameters 
1. RU (n=6);  
2. NU (n=4) 
10 PR NA Tachycardia, NS 
Cohen and 
Rickles, 1974 
Effects of MJ on 
cognition 
1. PLB NRU;  
2. PLB RU;  
3. MJ NRU; 
4.  MJ RU 
30 Learning (a list of 9 word paired associate consisting 
of a CVC trigram – nonsense syllable – and a word) 
Learning, trend level significance, PLB NRU > other 
groups, MJ NRU < other groups 
NA 
Babor et al., 
1975 
Effects of MJ on  
intoxication and cardiac 
parameters 
1. RU (n=11);  
2. NRU (n=7) 
18 Intoxication (7-point bipolar adjective scale, “stoned” 
vs “straight”), PR 
1. Intoxication, trend level significant ↓ upon 
continuous  MJ exposure only in RU 
2. Tachycardia: duration (effect 25 min after 
use) ↓only in RU, intensity (effect immediately 
after use) NS  
Benowitz 
and Jones, 
1975  
Effects of ∆9-THC and 
MJ on cardiac 
parameters 
CBSU 12 PR, supine BP, standing BP, BP after exercise, BP 
during Valsalva maneuver, BP in the supine position 
placing one hand to the wrist in ice water for 30 sec 
(Cold pressor test), ECG, plasma volume (Evans Blue 
dye method) 
NA 1. Supine hypotension, NS; 2. Orthostatic 
hypotension, ↓ over study period; 3. MJ-induced 
tachycardia, ↓ over ∆9-THC maintenance  
Jones et al., 
1976 
Effects of ∆9-THC, 
crude extract, and MJ 
on subjective effects, 
intoxication, 
psychopathology, 
cognition, cardiac 
parameters, sleep, and 
other physiological 
parameters 
RU 53 Mood (POMS), subjective effects (SCL-90), 
cognitive and psychomotor function, “psychedelic 
experience” (DEQ),sleep, PR, BP, Salivary flow, 
intraocular pressure, skin and body temperature, 
EEG, weight, haematocrit, haemoglobin, bilirubin, 
testosterone 
 
1. High-dose intoxication, ↓ after 96h of minimal but 
continuous intoxication; 2. Dose-dependent effect on 
intoxication no longer evident after 12 days; 3. 
Sedation, ↓ over study period; 4. Good feelings, NS; 5. 
Withdrawal symptoms, NS; 6. Increase in sleep duration 
and quality, ↓ over study period; 7. Cognitive and 
psychomotor impairment, ↓ over study period; 8. Mood 
changes, ↓ over study period 
9. Skin temperature decrease, 10. Salivary flow 
decrease, 11. Tachycardia, 12. Reduced BP 
(supine, NS), 13. Intraocular pressure decrease, 
14. Body temperature increase, and 15. EEG 
alpha slowing and auditory-evoked potential 
amplitude decreases, all ↓ over study period; 16. 
Weight gain, NS; 17. Serum haematocrit and 
haemoglobin decrease, NS; 18. Bilirubin decrease, 
NS 19. Plasma testosterone decrease, NS; 20. MJ-
induced tachycardia, ↓ in intensity and duration 
over ∆9-THC maintenance 
Nowlan and 
Cohen, 1977 
Effects of MJ on 
intoxication and cardiac 
parameters 
1. LU/ LMU 
(n=14-16);  
2. HMU (n=7-
8);  
3. HU (n =7-8) 
30  “High” (7-point bipolar adjective scale, “straight” or 
non-intoxicated vs highest ever been on MJ), PR 
1. “High”, ↓ over study period in whole group, partial 
recovery after 1-week abstinence; 2. “High”, ↓ during 
1st week in HU vs other groups combined; 3. “High”, 
more rapid and sharp↓ in HU than other groups, 4. 
“High”,  ↓ duration in HU vs other groups  
5. Tachycardia, ↓ over study period in whole 
group, partial recovery after 1-week abstinence; 
6. Tachycardia, LU/ LMU > HM > HU during 
1st week; 7. Tachycardia, more rapid ↓ in HU 
and MHU than LU 
Lindgren et 
al., 1981 
 
Effects of ∆9-THC and 
MJ on intoxication and 
cardiac parameters 
1. RU (n=9); 
2. NRU (n=9) 
18 “High” (10-point scale, no effect vs maximum effect 
the subject could imagine), PR 
1. “High”, NS 2. Tachycardia, NS 
Lex et al., 
1984 
Effects of ∆9-THC on 
subjective effects, 
cardiac parameters, and 
psychopathology 
1. RU (n=9); 
2. NRU (n=10) 
19 PR, intoxication (11-point scale, from “ not high at 
all” to “highest ever”), confusion (POMS) 
1. Intoxication: duration (effect 90 min after use) ↓only 
in RU; 2. Confusion: ↑ only in NRU 30 min after use; 3. 
Correlations between PR, intoxication, and confusion 
only in NRU 15 and 30 min after use 
4. Tachycardia: duration (effect 90 and 180 min 
after use) ↓only in RU 
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Mendelson et 
al., 1984 
Effects of ∆9-THC on 
the endocrine system 
1. RU (n=8); 
2. IU (n=7); 
3. NRU (n=8) 
23 Prolactin NA Prolactin, NS 
Marks et al., 
1989 
Effects of MJ on 
cognition 
1. NRU (n=6); 
2. NU (n=6) 
12 Divided attention (eight 5-min blocks, each 
containing 30 signals in random order but with an 
equal probability of either central or peripheral 
signals occurring) 
Divided attention: peripheral signal detection, dose-
dependent impairment NRU < NU; central signal 
detection, NS 
NA 
Haney et al., 
1999 
Effects of ∆9-THC on 
subjective effects, 
cognition, food intake, 
and social behavior 
RU 12 Drug effect and physical symptoms (50-item VAS, 
100-mm line, “not at all” to “extremely”), 
“psychedelic experience” (DEQ), learning, memory, 
vigilance, and psychomotor ability (DSST, DAT, 
RIT, Immediate and Delayed DRT), food intake, 
verbal and non-verbal social behavior 
1. Subjective effects ↓ over study period; 2. Drug-effect 
(dose strength, dose liking, willingness to take the dose 
again) ↓ over study period; 3. Food intake, NS; 4. Social 
behavior, NS; 5. No effect on cognition apart from DAT 
performance impaired on day 1 at high ∆9-THC dose 
NA 
Kirk and De 
Wit, 1999 
Effects of ∆9-THC on 
subjective effects, 
cognition, and cardiac 
parameters 
1. RU (n=11); 
2. NRU (n=10) 
21 MJ-like effects and sedation (53-item version of the 
ARCI), VAS ( “not at all” to “very”); “psychedelic 
experience” (DEQ), overall experience (End-of-
session questionnaire), psychomotor ability (DSST), 
PR 
1. Lower dose, “Feel” and “High” only in RU; 2. 
Higher dose, sedative-like effects, RU < NRU; 3. Higher 
dose, stimulant-like effects ↓ only in NRU; 4. Higher 
dose, liking effects↓ only in NRU; 5. Psychomotor 
performance, NS; 6. Other subjective effects, NS; 7. 
Willing to take again, NS 
8.  Tachycardia, NS 
Hart et al., 
2002 
Effects of ∆9-THC and 
MJ on subjective 
effects, cognition, sleep, 
and food intake 
RU 12 Drug effect and physical symptoms (50-item VAS, 
100-mm line, “not at all” to “extremely”), 
“psychedelic experience” (DEQ), learning, memory, 
vigilance, and psychomotor ability (DSST, RAT, 
DAT, RIT, Immediate and Delayed DRT) 
1. MJ-induced subjective effects ↓ over ∆9-THC 
maintenance; 2. MJ-induced impairment in DRT ↓over 
∆9-THC maintenance and at higher dose, but other 
psychomotor performance NS; 3. Reinforcing effects, NS; 
4. Food intake, NS; 5. Sleep, NS 
NA 
Ponto et al., 
2004 
Effects of MJ on  
intoxication, cardiac 
parameters,  
pharmacokinetics, and 
other physiological 
parameters  
1. RU (n=12);  
2. NRU (n=24) 
36 “High”, PR, BP, arrival time of bolus, rCBF 
(pharmacokinetics of [15O] water), ∆9-THC levels  
 
1. “High” and related duration, RU < NRU 2. ∆9-THC levels, RU > NRU, even correcting 
for baseline; 3.  Tachycardia, related change, 
and duration, RU < NRU; 4. RPP, related 
change, and duration, RU < NRU; 5. Systolic 
BP, NS; 6. Diastolic BP, NS; 7. Arrival time of 
bolus, NS; 8. rCBF, NS; 9. Correlations between 
“high” and cardiovascular function, significant 
only in NRU; 10. Correlations between bolus 
arrival time/ rCBF and cardiovascular function, 
NRU > RU    
D’Souza et 
al.,2008a 
Effects of ∆9-THC on  
cognition and endocrine 
system 
1. RU (n=11);  
2. NRU (n=17) 
28 Verbal learning and immediate and delayed recall 
(VLT), vigilance (CPT), executive function, spatial 
memory, and visual recognition memory (CANTAB),  
speed and accuracy (MOT), akathisia and drug-
induced Parkinsonism (BARS), prolactin 
1. Impaired immediate recall (in combination with 
haloperidol), RU < NRU (effect only in NRU); 2. 
Impaired attention, NS; 3. Impaired spatial working 
memory, RU < NRU; 4. other performance, NS   
5. Prolactin, NS (RU < NRU at baseline)    
D’Souza et 
al.,2008b 
Effects of ∆9-THC on  
intoxication, 
psychopathology, 
cognition, cardiac 
parameters, 
pharmacokinetics, and 
endocrine system 
1. RU (n=30);  
2. NRU (n=22) 
52 Psychotomimetic symptoms (PANSS), perceptual 
alterations (CADSS), anxiety and intoxication (VAS), 
Verbal learning and immediate and delayed recall 
(VLT), vigilance (CPT);  PR, ∆9-THC and THC-
COOH levels, cortisol, prolactin 
1. Perceptual alterations, RU < NRU; 2. 
Psychotomimetic symptoms, RU < NRU; 3. “High”, NS; 
4. Anxiety, RU < NRU; 5. “Calm and relaxed”, NS; 6. 
Impaired immediate recall and delayed free recall, RU 
< NRU (RU > NRU at baseline); 7. Delayed recognition 
recall, NS; 8. Impaired attention, NS  
9.  Tachycardia, NS; 10. ∆9-THC levels, NS; 11. 
THC-COOH levels, NS (RU > NRU at baseline); 
12. Cortisol increase, RU < NRU; 13. Prolactin 
(overall), RU < NRU    
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D’Souza et 
al.,2009 
Effects of ∆9-THC on 
psychopathology, 
cognition, and 
neurochemistry     
1. RU (n=9);  
2. NRU (n=14) 
23 Psychotomimetic symptoms (PANSS), perceptual 
alterations (CADSS), “High” (VAS), spatial memory, 
BDNF 
1. Perceptual alterations, RU < NRU; 2. 
Psychotomimetic symptoms, RU < NRU; 3. Impaired 
spatial working memory, RU < NRU 
4. Increased BDNF, RU < NRU (increase only in 
NRU) 
Ramaekers 
et al., 2009 
Effects of ∆9-THC MJ 
on intoxication, 
cognition, cardiac 
parameters, and 
pharmacokinetics  
1. RU (n=12);  
2. NRU (n=12) 
24 “High” (VAS, 100-mm line), psychomotor ability 
(CTT), attention (DAT), motor impulsivity (SST), 
executive function and planning (TOL), PR, BP, ∆9-
THC, 11-OH-THC, and THC-COOH levels  
1. “High”, RU < NRU; 2. CTT impaired performance, 
RU < NRU (effect only in NRU); 3. DAT impaired 
performance, ↑ during 1st h only in NRU; 4. Other 
performance, NS; 5. Increase in the proportion of 
cognitive impairment observations in NRU for all 
domains, in RU only for SST at high ∆9-THC levels 
(>10 ng/ml) 
6. PR, RU < NRU; 7. BP, NS; 8. ∆9-THC, 11-
OH-THC, and THC-COOH levels, RU > NRU 
Ranganathan 
et al., 2009 
Effects of ∆9-THC on 
pharmacokinetics and 
endocrine system  
1. RU (n=40);  
2. NRU (n=36) 
76 ∆9-THC and THC-COOH levels, cortisol, prolactin NA  1.  Dose-dependent cortisol increase, RU < 
NRU; 2. Prolactin (overall), RU < NRU; 3. ∆9-
THC levels, NS; 4. THC-COOH levels, NS (RU > 
NRU at baseline)   
Bedi et al., 
2010 
Effects of dronabinol on 
subjective effects, 
psychopathology, 
cognition, sleep, and 
food intake 
RU 7 Food intake, weight, subjective hunger and satiety 
(HSQ), food cravings (FDQ), mood (VAS), 
“psychedelic experience” (DEQ), Sleep (Nightcap 
sleep monitor and sleep quality VAS), learning, 
memory, vigilance, and psychomotor ability (DSST, 
RAT, DAT, RIT, Immediate and Delayed DRT),  
verbal and non-verbal social behavior  
1. Increased caloric intake, ↓ over study period (not 
different from PLB in 2nd half of study period); 2. Sleep 
satisfaction, ↑ over 1st half of study period only; 3. 
Subjective effects, NS, 4. Cognition, NS; 5. Social 
behavior, NS; 6. Satiety, ↑ over 1st half of study period 
only (hunger ↑ over 2nd half of study period only, other 
parameters, NS); 7. Food craving, ↑ for protein/ fat over 
1st half of study period only (for carbohydrate over 2nd 
half of study period only)  
8. Sleep efficiency ↑ only over 1st half of study; 
9. Weight, NS      
Böcker et al., 
2010 
Effects of ∆9-THC on  
electrophysiology 
1. RU (n=12);  
2. NRU (n=11) 
23 EEG, ERP task (visual selective attention 
Task; SFD80, FSP, OSN) 
NA 1. SFD80, RU < NRU; 2. OSN, ↓ linearly with 
cannabis dose only in NRU; 3. FSP,  RU < NRU 
Barkus et al., 
2011 
Effect of ∆9-THC on 
psychopathology, 
pharmacokinetics, and 
neurochemistry 
CBSU 9 Psychotomimetic symptoms (PANSS), 
dopamine release ([123I]IBZM SPET scanning 
session, 185 MBq), ∆9-THC levels 
1. Positive symptoms, negative correlation with 
previous cannabis use 
2. Dopamine release, NS; 3. ∆9-THC levels 
(AUC), NS 
Bosker et al., 
2012 
Effect of ∆9-THC on 
intoxication, 
pharmacokinetics, and 
driving 
1. RU (n=12); 
2. NRU (n=12) 
24 Driving (Road-tracking test, SDLP, TSA), 
impairments during on-the-road driving (SFST), 
“high” (VAS, 100-mm line, “not at all” to “most 
ever”), ∆9-THC, 11-OH-THC, and THC-COOH 
levels 
1. SDLP impairment, RU < NRU (however, 25% RU still 
displaying driving impairments ≥ Blood alcohol 
concentrations of 0.5 mg/ml (0.05 g%); 2. TSA 
impairment, RU < NRU; 3. SFST, NS; 4. “high”, NS 
5. ∆9-THC, 11-OH-THC, and THC-COOH 
levels, RU > NRU 
D’Souza et 
al.,2012 
Effect of ∆9-THC on  
intoxication, 
psychopathology, and 
electrophysiology 
1. RECU 
(n=14);  
2. NRECU 
(n=12) 
26 Psychotomimetic symptoms (PANSS), 
perceptual alterations (CADSS), “High” (VAS),  
EEG, ERP task (three-stimulus auditory “oddball” 
P300 task) 
1. Perceptual alterations, RECU < NRECU; 2. 
Psychotomimetic symptoms, RECU < NRECU; 3. 
Behavioral measures, NS 
4. P300b amplitude and latency, NS; 5. P300a 
amplitude, NS; 6. P300a peak latency, RECU < 
NRECU 
Theunissen 
et al., 2012 
Effect of MJ on   
subjective effects, 
intoxication, cognition, 
pharmacokinetics, and  
electrophysiology 
1. RU (n=12); 
2. NRU (n=12) 
24 ”High” (VAS, 100-mm line, “not at all” to 
“maximally high”),  EEG, ERP task (DAT, P100 and 
P300; SST, N200), ∆9-THC, 11-OH-THC, and THC-
COOH levels 
1. “High” (immediately after smoking), RU < NRU; 2. 
DAT impaired performance, RU < NRU (effect specific 
to NRU); 3. Behavioral measures, NS 
4. ∆9-THC, 11-OH-THC, and THC-COOH 
levels, RU > NRU; 5. P100 amplitude, ↓ in NRU 
(while trend level significant ↑ in RU); 6. P100 
latency, NS; 7. P300, NS; 8. N200, NS 
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Fabritius et 
al., 2013 
Effect of ∆9-THC on 
intoxication,  
psychopathology, and  
pharmacokinetics 
1. RU (n=23); 
2. NRU (n=25) 
48 Subjective effects (VAS, 100-mm line), ∆9-
THC, 11-OH-THC, and THC-COOH levels 
1. Intoxication duration RU < NRU; 2. Confusion  
intensity and duration, RU < NRU 
3. ∆9-THC, 11-OH-THC, and THC-COOH 
levels, RU > NRU at baseline for all, after 
administration for 11-OH-THC and THC-
COOH (however NS after correcting for baseline 
levels) 
Gorelick et 
al., 2013 
Effect of ∆9-THC on  
subjective effects,  
cardiac parameters, and   
pharmacokinetics 
RU 13 Subjective effects (VAS, 100-mm line), PR, 
BP, ∆9-THC and 11-OH-THC 
1. Intoxication (“high” and “stoned”) and “Good drug 
effect”, ↓ over study period 
2. Hypotension, NS; 3. Tachycardia, NS; 4. ∆9-
THC and 11-OH-THC levels, increasing over time 
Sewell et al., 
2013 
Effect of ∆9-THC on 
cognition 
1. RECU 
(n=10); 2. 
NRECU (n=34) 
44 TET, TPT 1. TET impairment, effect only in NRECU; 2. TPT  
impairment, effect only in NRECU 
NA 
Vandrey et 
al., 2013 
Effect of ∆9-THC and 
dronabinol on  
subjective effects and 
cardiac parameters 
RU 13 Withdrawal (MWC), sleep (diary and VAS), 
craving (MCQ), drug effects (ARCI), PR 
1. Subjective effects, NS 
 
2.  Cannabis-induced tachycardia, ↓ over high-
dose ∆9-THC maintenance  
Cortes-
Briones et 
al., 2015 
Effect of ∆9-THC on 
electrophysiology 
1. RECU (n=9);  
2. NRECU 
(n=11) 
20 EEG, ASSR task (three-stimulus auditory 
“oddball” inter-trial coherence and evoked power 
task) 
NA 1. Inter-trial coherence, RECU < NRECU at 
trend level significance; 2. Evoked power, 
RECU < NRECU 
Desrosiers et 
al., 2015 
Effects of ∆9-THC MJ 
on subjective effects, 
intoxication, 
psychopathology, 
cognition, cardiac 
parameters, and 
pharmacokinetics 
1. RU (n=14);  
2. NRU (n=11) 
25 “High” (VAS, 100-mm line), psychomotor 
ability (CTT), attention (DAT), working memory (N-
Back task),  risk taking and impulsivity (BART, 
MDMQ, BIS, ZKPQ, RPQ),  BP, PR, ∆9-THC levels    
1. “High” and anxiety, RU < NRU; 2. Duration of 
subjective effects (“difficulty concentrating”, “altered 
sense of time”, “feel hungry”, “feel thirsty”, “shakiness/ 
tremulousness”, “dry mouth or throat”), RU < NRU; 3. 
CTT impaired performance, RU < NRU; 4. DAT, hits, 
RU > NRU; 5. DAT, ↑ tracking errors, false alarms, 
and reaction times only in NRU; 6. N-Back performance, 
NS (however, N-Back RT decrease, RU < NRU; 7. 
BART, NS; 8. Positive correlations between BART, BIS, 
ZKPQ, and RPQ only in NRU (some at trend level 
significance) 
9. ∆9-THC levels, RU > NRU; 10. Tachycardia, 
RU < NRU; 11. Increased systolic and diastolic 
BP, RU < NRU 
Farris et al., 
2016 
Effects of ∆9-THC MJ 
on breath-holding 
duration 
1. RU;  
2. NRU 
88 Breath-holding task (index of respiratory 
distress intolerance), puff count 
1. Puff count, NS 2. Post-smoking breath-holding duration, ↓ only 
in NRU 
Ramaekers 
et al., 2016 
Effects of ∆9-THC on 
intoxication, cognition, 
and pharmacokinetics 
1. LU (n=33);  
2. LMU (n=41);  
3. MHU (n=23);  
4. HU (n=25) 
122 Intoxication (VAS,100-mm line, “no 
intoxication” to “extremely intoxicated”), 
psychomotor ability (CTT), attention (DAT), motor 
impulsivity (SST), executive function and planning 
(TOL), ∆9-THC, 11-OH-THC, and THC-COOH 
levels 
1. CTT impaired performance, ↓ with increasing 
frequency of CBS use; 2. Other performance, NS; 3. 
Intoxication, ↓ with increasing frequency of CBS use at 
trend level significance 
4. ∆9-THC, 11-OH-THC, and THC-COOH, NS 
Newmeyer et 
al., 2017a 
Effects of ∆9-THC on 
subjective effects, 
intoxication, cardiac 
parameters, 
pharmacokinetics, and 
other physiological 
1. RU (n=11); 
2. NRU (n=9) 
20 Subjective effects (VAS), PR, BP, respiration 
rate, expired CO (Breath CO monitor)  
1. “Good drug effect”, “high”, and “stoned”, oral 
effects only in NRU; 2. Willingness to drive, ↓ only in 
NRU after oral dosing; 3. CBS craving, ↓ only in RU 
after smoking and/ vs vaporization (baseline-adjusted); 
4. “Good drug effect” and “stoned”, vaporization > oral 
only in RU; 5. “Good drug effect” positive correlation 
7. ∆9-THC and 11-OH-THC levels, RU > NRU; 
8. 11-OH-THC levels, oral > vaporized in NRU 
only; 9. Tachycardia positive correlation with 
∆9-THC levels after oral dosing only in NRU; 
10. BP, NS; 11. Respiration rate, NS; 12. Expired 
CO, NS  
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MJ, marijuana; ∆9-THC, delta-9-tetrahydrocannabinol; RU, regular users; NRU, non-regular users; IU, intermittent users; PLB, placebo; CBSU, cannabis users; LU, light users; LMU, low moderate users; HMU, high moderate users; HU, heavy 
users; RECU, recent   users; NRECU, non-recent users; DEQ, Katz-Waskow subjective Drug Effects Questionnaire; CPT, Continuous Performance Test; DSST, Digit-Symbol Substitution Test; TPT, Time Perception Test; SCWT, Stroup Color-
Word interference Test; POMS, Psychiatric Outpatient Mood Scale; PR, pulse rate; CVC trigram, consonant, vowel, and consonant trigram; BP, blood pressure; sec, seconds; ECG, electrocardiogram; EEG, electroencephalogram; SCL-90, 
Symptom Checklist-90; VAS, Visual Analogue Scale; DAT, Derived Attention Task; RIT, Rapid Information Task; DRT, Digit-Recall Task; SFD80, Spatial Frequency-Dependent potential at about 80 ms; OSN, Occipital Selection Negativity; 
FSP, Frontal Selection Positivity; TET, Time Estimation Task; TPT, Time Production Task; ARCI, Addiction Research Center Inventory; RAT, Repeated Acquisition Task; rCBF, regional Cerebral Blood Flow; PANSS, Positive and Negative 
Syndrome Scale; CADSS, Clinician Administered Dissociative Symptoms Scale; VLT, Verbal Learning Test; CANTAB, Cambridge Neuropsychological Test Automated Battery; MOT, Motor Screening Task; BARS, Barnes Akathisia Rating 
Scale; BDNF, Brain-Derived Neurotrophic Factor; CTT, Critical tracking task; SST, Stop-Signal Task; TOL, Tower of London; THC-COOH, 11-nor-9-carboxy-delta-9-tetrahydrocannabinol; HSQ, Hunger-Satiety Questionnaire; FDQ, Food 
Desirability Questionnaire; SDLP, TSA, Time to speed adaption; Standard Deviation of Lateral Position; SFST, Standardized Field Sobriety Test; 11-OH-THC, 11-hydroxy-delta-9-tetrahydrocannabinol; CBN, cannabinol; CBD, cannabidiol; 
ERP task, Event-related potential task; MWC, Marijuana Withdrawal Checklist; MCQ, Marijuana Craving Questionnaire; THC-glucuronide, delta-9-tetrahydrocannabinol glucuronide; THCCOO-glucuronide, 11-nor-9-carboxy-delta-9-
tetrahydrocannabinol glucuronide; ASSR, Auditory Steady-State Response; BART, Balloon Analog Risk Task; MDMQ, Melbourne Decision Making Questionnaire; BIS, Barratt Impulsiveness Scale; ZKPQ, Zuckerman-Kuhlman Personality 
Questionnaire; RPQ, Risk Perception Questionnaire; CO, carbon monoxide; OLS, One Leg Stand; WAT, Walk And Turn; NS, not significant; NA, not assessed/ not applicable; >, higher/ better; <, lower/ poorer; ↓, reduction; ↑, increase; h, hour; 
RT, reaction time; min, minutes; RPP, Pulse rate x systolic blood pressure 
  
parameters with ∆9-THC and 11-OH-THC levels after oral dosing 
only in NRU; 6. “High” positive correlation with ∆9-
THC levels after oral dosing only in NRU 
Newmeyer et 
al., 2017b 
Effects of ∆9-THC on 
pharmacokinetics 
1. RU (n=11); 
2. NRU (n=9) 
20 Impairments during on-the-road driving 
(SFST:  OLS, WAT)  
1. OLS impairment, oral effect only in NRU; 2. WAT 
impairment, oral effect only in NRU; 3. OLS and WAT 
impairment positive correlation with ∆9-THC and 11-
OH-THC levels after oral dosing only in NRU 
4. ∆9-THC levels, RU > NRU; 5. ∆9-THC levels 
decrease, RU < NRU 
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Table 2. Methodological quality of human studies investigating development of tolerance in cannabis users 
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Study Study design Defined study 
population 
Age 
(years) 
Gender Cannabis/           
∆9-THC 
concentration 
Adequate 
exposure 
Comparability 
of subjects 
Placebo 
controlled 
Physical and mental 
health comorbidity 
Excluded/adjusted for 
tobacco, alcohol, and 
substance use 
Statistical 
analyses 
Funding or 
sponsorship 
Meyer et al., 
1971 
✓/✕ Double-
blind, 
counterbalanced; 
not randomized  
✓ 1. RU, daily 
CBS use or nearly 
so; 2. NRU, CBS 
use ≤ 1 per week 
✕ ✕ ✓250 mg of 
MJ leaf (0.9% 
∆9-THC) or a 
self-selected 
known amount 
of MJ 
✓Half h smk. at 
libitum from a pipe 
for 3 weekly 
sessions (420 mg by 
NRU, 380 mg by 
RU, NS) 
✕ ✓ ✓/✕Exclusion 
criterion (by psychiatric 
interviews and 
psychological test); 
physical health not 
assessed 
✕ ✕ ✓ 
Renault et al., 
1971 
✓/✕ Double 
blind; not 
randomized or 
counterbalanced 
✓ 1. RU, current 
CBS use ≥ 1 per 
week; 2. NU, 
lifetime CBS use 
range: 0-3 times 
✓ 
24-45 
(range) 
✓Male ✓ 62.5, 125, 
250, 435 mg of 
MJ (1.5% ∆9-
THC) 
✓smk. from a 
crucible or pipe 
✕ ✓ ✓Exclusion criterion 
(by routine medical 
history, physical 
examination, blood 
count, urinalysis, chest 
x-ray, and psychiatric 
evaluation) 
✓/✕All regular 
tobacco users; alcohol 
and other substance use 
not assessed 
✕ ✓ 
Cohen and 
Rickles, 1974 
✓/✕ Double 
blind, 
randomized; not 
counterbalanced 
✓1. RU, CBS use 
≥ 4 per week; 2. 
NRU, CBS use at 
weekend (over 
previous year) 
✕ ✓Male ✓1 mg of MJ 
(1.4% ∆9-
THC) per cig. 
✓2 cig. on 2 
occasions 7 days 
apart 
✓/✕ Matched 
for WAIS IQ; not 
for other 
demographic 
characteristics   
✓ ✕  ✕ ✓
ANOVA, 
Duncan’s 
Extended 
Range test 
✓ 
Babor et al., 
1975 
✕ ✓1. RU, daily 
CBS use; 2. NRU, 
CBS use > 5 per 
month but < daily 
(over previous 
year) 
✓ 
21-26 
(range) 
✓Male ✓~1 mg of MJ 
(~2.1% ∆9-
THC) per cig. 
✓ 21-day drug 
period of smk. MJ 
cig. on a free-
choice basis 
✓ Matched for  
demographic 
characteristics 
(age, years of 
education) 
✕ ✓Exclusion criterion 
(by clinical and 
laboratory 
examinations) 
✓/✕ NS difference in 
alcohol, hallucinogens, 
and amphetamine use; 
tobacco use not 
assessed 
✓ Pearson 
correlation 
✓ 
Benowitz and 
Jones, 1975 
✓/✕ Double 
blind; not 
randomized or 
counterbalanced 
✓CBS use range: 
2-21 cig. per week 
(M: 9); 1. RU, 
15.2±5.3 joints 
per week; 2. 
NRU, 4.7±2.2 
joints per week 
(M±SD) 
✓ 
20-27 
(range), 
25.1±2.2 
(M±SD)  
✓Male ✓1. 0 to 30 mg 
of ∆9-THC per 
caps.; 2. 20 mg 
of ∆9-THC per 
MJ cig. 
✓18-20-day drug 
period of po. ∆9-
THC maintenance 
(1 caps. every 4 h; 
up to 210 mg of ∆9-
THC per day), with 
MJ cig.  
administered 
periodically 
✕ However 
study participants 
evaluated as a 
whole group 
✓ ✓Exclusion criterion 
(by physical and 
neurological 
examination, screening 
blood and UDS, chest 
x-ray, ECG, and EEG)  
✓Exclusion criterion 
for heroin, barbiturate, 
and amphetamine use; 
alcohol and tobacco use 
not assessed, however, 
subjects were asked not 
to use any drug for one 
week prior to study 
✓
ANOVA, 
Dunnet 
post test 
✓ 
Jones et al., 
1976 
✓/✕ Double-
blind, cross-
over; not 
randomized or 
counterbalanced 
✓ RU, CBS use 
≥ 2 per week 
(most with daily 
use) 
✓ 
21-31 
(range), 
25 (M) 
✓Male ✓1. 10-30 mg 
of pure ∆9-
THC (96%) per 
caps.; 2. crude 
extract (29% 
∆9-THC, 1.5% 
CBN, 2.8% 
CBD) 
dissolved in 
0.2-0.4 cm3 of 
✓21-42-day drug 
period of po. ∆9-
THC or crude 
extract (∆9-THC + 
other cannabinoids) 
admin. every 4h, 
with MJ cig. 
administered 
periodically 
NA 
 
✓ ✓Exclusion criterion 
(by clinical and 
laboratory 
examinations); all in 
good physical and 
emotional health 
✓/✕ alcohol 3-4 
times per week; 
minimal involvement 
with other substances; 
tobacco use not 
assessed 
✓ANOVA ✓ 
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95% ethanol 
solution; 3. 1 g 
of MJ (2.2% 
∆9-THC) per 
cig.  
Nowlan and 
Cohen, 1977 
✕ ✓ 1. L+LM, 2.1 
to 4.3 cig. per day; 
2. HM, 6.2 cig. 
per day; 3. H, 8.5 
cig. per day (over 
study period) 
✓ 
21-35 
(range) 
✓Male ✓900 mg of 
MJ (2.2% i.e. 
19.8 mg ∆9-
THC) per cig. 
✓64-day drug 
period of smk. at 
least 1 MJ cig. per 
day with a daily ad 
libitum period 
(from 4 pm to 
midnight) 
✕ However 
study participants 
evaluated both 
separated and as 
a whole group 
✕ ✓Exclusion criterion 
(by physical 
examination, laboratory 
tests, psychiatric 
interview, and MMPI) 
✓/✕ Minimal 
involvement with other 
substances in at least 
previous 6 months; 
alcohol and tobacco use 
not assessed 
 
✕ ✓ 
Lindgren et 
al., 1981 
 
✓/✕
Counterbalanced
, cross-over; not  
double-blind or 
randomized 
✓ 
1. RU, daily CBS 
use (CBS in urine 
and plasma); 2. 
NRU, CBS use ≤ 
1 per month (no 
CBS in urine and 
plasma) 
✓ 
19-36 
(range) 
✓ Male (n 
= 16), 
Female (n = 
2) 
✓1. 19 mg ∆9-
THC (1.64%) + 
0.23% CBN 
per MJ cig.; 2. 
2 mg/ml IV ∆9-
THC (5.0 mg) 
in 95% ethanol 
solution   
✓2 single admin. 
(1 MJ cig. and 1 IV 
∆9-THC injection 
over 2 min) at least 
4 days apart 
✕ ✓ ✓Exclusion criterion; 
all were in good 
physical and mental 
health, no one was on 
any psychoactive 
medication 
✓No significant use of 
substances other than 
MJ; abstinent from 
alcohol for at least 24h 
prior to experiment   
✕ ✓ 
Lex et al., 
1984 
✓/✕ Double-
blind; not 
randomized or 
counterbalanced 
✓ 
1. RU, CBS use ≥ 
6 times per week 
in last 3 months, 
regular use for at 
least 2 years; 2. 
NRU, CBS > 2 
per month but < 5 
per week in last 3 
months 
✓ 
21-36 
(range), 
26.1±4.3
5 
(M±SD) 
✓ Female ✓1.8% ∆9-
THC) per cig. 
✓1 single admin. 
of 1 MJ cig. 
(controlled 
inhalation: 1 
puff/30 s, smoke 
retention: 2- 4 s). 
 
✓ Matched for  
demographic 
characteristics 
(age, years of 
education) 
✓ ✓Exclusion criterion 
(by clinical and 
laboratory 
examinations); all in 
good physical and 
mental health 
✓/✕  Matched for 
alcohol and substance 
use status; exclusion 
criterion for alcohol 
and other substance use 
disorders; tobacco use 
not assessed  
✓ 
Correlation 
✓ 
Mendelson et 
al., 1984 
✓/✕ Double-
blind; not 
randomized or 
counterbalanced 
✓ 
1. RU, daily CBS 
use (1-3 MJ 
cigarettes) for at 
least one year; 2. 
IU, weekly CBS 
use (1-3 MJ 
cigarettes) for at 
least one year; 3. 
NRU, monthly 
CBS use (1-3 MJ 
cigarettes) for at 
least one year 
✓ 
1. RU, 
23-30 
(range), 
26.8 (M); 
2. IU, 22-
30 
(range), 
25.3 (M); 
3. NRU, 
22-28 
(range), 
24.4 (M)  
✓ Male ✓1. 1 g of MJ 
(1.83% ∆9-
THC) per cig.; 
2. 2 mg of oral 
Nabilone; 3. 
17.5 mg of ∆9-
THC per caps. 
✓5-day drug 
period of active 
drug admin (one 
dose of  Nabilone, 
∆9-THC, or MJ per 
day)   
✓/✕ Age and 
weight reported; 
however 
differences in 
demographic 
characteristics 
not formally 
tested   
✓ ✓Exclusion criterion 
(by clinical and 
laboratory 
examinations); all in 
good physical and 
mental health 
✓/✕ Exclusion 
criterion for alcohol 
and other substance use 
disorders; tobacco use 
not assessed 
✓ t-test ✓ 
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Marks et al., 
1989 
✓/✕Repeated 
measure; not  
double-blind or 
randomized 
✓ 
1. NRU, weekly 
CBS use (M: 3 
joints per week, 
range: 1.5-6); 2. 
NU 
✓ 
23.4±2.6 
(M±SD) 
✓ Male (n 
= 6), 
Female (n = 
6) 
✓770 mg of 
MJ (1.31% ∆9-
THC) + extra 
70 mg and/or 
detoxified plant 
material per 
cig. 
✓9-day drug 
period of smk. 1 MJ 
cig. per day over a 
10-min period at 3 
different doses (0, 
2.6, and 5.2 ∆9-
THC mg), alone or 
combined with 
alcohol 
✓/✕ Matched 
for gender; not 
for other 
demographic 
characteristics   
✓ ✕ ✓/✕NS difference in 
alcohol use (all regular 
users, M: 13 drink units 
per week); no use of 
other substances over 
the previous 24 h; 
tobacco use not 
assessed 
✓
ANOVA, 
multiple 
testing 
correction, 
Duncan’ 
test 
✓ 
Haney et al., 
1999 
✓/✕Repeated 
measure; not  
double-blind or 
randomized 
✓ 
RU, CBS use: 
6.4±0.4 days per 
week (M±SD), 
range: 1-8 cig. per 
occasion 
✓ 
21-29 
(range), 
24.7±3.5 
(M±SD) 
✓ Male (n 
= 6), 
Female (n = 
6) 
✓20 or 30 mg 
of ∆9-THC per 
caps. 
✓20-day drug 
period of po. ∆9-
THC admin., 4 
times/ day 
✕ However 
study participants 
evaluated as a 
whole group 
✓ ✓Exclusion criterion 
(by medical and 
psychiatric evaluations) 
✓/✕Most with 
weekly alcohol use (M: 
1 day/week, two drinks 
per occasion); 9 
tobacco users (also 
during experiment); 
other substance use 
infrequent (only CBS in 
urine on study day) 
✓
ANOVA, 
Hunyh-
Feldt 
correction 
✓ 
Kirk and De 
Wit, 1999 
✓/✕Double-
blind; not 
randomized or 
counterbalanced  
✓1. RU, lifetime 
CBS use ≥ 100 
times, current use 
≥ 2 per month; 2. 
NRU, lifetime 
CBS use ≤ 10 
times, no use in 
past 4 years 
✓1. RU, 
27.6±5.2; 
2. NRU, 
25.1±3.6  
(M±SD) 
 
✓ Male (n 
= 12), 
Female (n = 
9) 
✓7.5 or 15 mg 
of ∆9-THC per 
caps. 
✓3 evening 
sessions once per 
week  
✓Matched for 
demographic 
characteristics 
(age, gender) 
✓ ✓Exclusion criterion 
(by  DSM-IV 
psychiatric interview, 
SCL-90, ECG, and 
physical examination) 
✓/✕Asked not to use 
tobacco for 6h and any 
substance for 24h  prior 
to study; alcohol free 
on study visit; however, 
RU > NRU on lifetime 
use of other substances, 
tobacco and alcohol 
✓ANOVA ✓ 
Hart et al., 
2002 
✓/✕ Double-
blind, within-
participant; not 
randomized or 
counterbalanced 
✓ 
RU, daily CBS 
use (M: 12 joints 
per day, range: 1-
35) 
✓ 
21-45 
(range), 
31.7 (M) 
✓ Male (n 
= 10), 
Female (n = 
2) 
✓1. 1.8% ∆9-
THC per MJ 
cig.; 2. 0-20 mg 
of ∆9-THC per 
caps. 
✓18-day drug 
period of smk. 1 MJ 
cig. on 5 occasions 
daily and receiving 
4 ∆9-THC caps. 
NA ✓ ✓Exclusion criterion 
(by medical and 
psychological 
evaluations) 
✓/✕8 current alcohol 
users (range: 1-10 
drinks per week); 7 
current tobacco users 
(range: 2-20 cig. per 
day); negative UDS on 
study day 
✓ANOVA ✓ 
Ponto et al., 
2004 
✓/✕
Randomized, 
cross-over; not  
double-blind or 
counterbalanced 
✓1. RU, CBS use 
≥ 7 times per 
week (M: 1.8 per 
day); 2. NRU, 
CBS use < 10 
times per month 
(M: 1 per week) 
✓ 
1. RU, 
20-36 
(range), 
21.7 (M); 
2. NRU, 
20-36 
(range), 
22.6 (M) 
✓ Male (n 
= 18), 
Female (n = 
18) 
✓20 mg ∆9-
THC per MJ 
cig. 
✓1 single admin. 
of 1 MJ cig.  
✓ Matched for 
demographic 
characteristics 
(age, gender) 
✓ ✕ ✓/✕ Negative UDS 
on study day; alcohol 
and tobacco use not 
assessed 
✓
ANOVA, t-
test 
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D’Souza et 
al.,2008a 
✓ Double-
blind, 
randomized, 
counterbalanced 
✓1. RU, lifetime 
CBS use ≥ 100 
times, last use 
within past week, 
recent use ≥ 10 
per month (CBS 
in urine), CUD 
DSM-IV criteria; 
2. NRU, lifetime 
CBS use from < 5 
to > 100 times, no 
use in past week 
✓ 
18-55 
(range), 
25±7 
(M±SD) 
✕ ✓ 2 ml IV ∆9-
THC (0.0286 
mg/kg)  in 95% 
ethanol 
solution 
✓1 single IV 
admin. of ∆9-THC 
over 20 min on 2 
occasions at least 7 
days apart 
✓ Matched for 
demographic 
characteristics 
(age, IQ, race, 
weight); years of 
education, RU < 
NRU 
 
✓ ✓Exclusion criterion 
(by DSM psychiatric 
interview for Axis I 
disorders + no family 
history of DSM Axis I 
disorder; and a general, 
physical, and 
neurological 
examination, ECG, and 
laboratory tests) 
✓/✕ Exclusion 
criterion for alcohol 
and other substance use 
disorders; asked to 
refrain from alcohol 
and  substances for 2 
weeks prior to study 
(apart from RU asked 
to refrain from CBS 
only for 24h prior to 
study visits); tobacco 
use not assessed 
✓ Non-
parametric  
mixed 
model, 
Bonferroni 
correction 
✓ 
D’Souza et 
al.,2008b 
✓ Double-
blind, 
randomized, 
counterbalanced 
✓1. RU, lifetime 
CBS use > 50 
times, last use ≥ 
10 in past month 
(CBS in urine), 
CUD DSM-IV 
criteria; 2. NRU, 
lifetime CBS use 
from < 5 to > 100 
times, no use in 
past week, use ≤ 1 
in past month (no 
CBS in urine) 
✓ 
18-55 
(range); 
1. RU, 
24.8±5.5; 
2. NRU, 
29±11.6 
(M±SD) 
✓ Male (n 
= 35), 
Female (n = 
17) 
✓2 ml IV ∆9-
THC (2.5 or 
5.0 mg)  in 
95% ethanol 
solution 
✓1 single IV 
admin. of  ∆9-THC 
on 2 occasions  at 
least 7 days apart, at 
2 different doses 
✓ Matched for 
demographic 
characteristics 
(age, gender, 
education, socio-
economic status); 
age and IQ used 
as covariates (as 
IQ differed 
between RU and 
NRU) 
✓ ✓Exclusion criterion 
(by  DSM-IIIR or IV 
psychiatric interview 
for Axis I disorders + 
no family history of 
DSM Axis I disorder; 
and a general, physical, 
and neurological 
examination, ECG, and 
laboratory tests) 
✓ Matched for smk. 
status; exclusion 
criterion for nicotine 
and other substance use 
disorders; asked to 
refrain from alcohol 
and substances for 2 
weeks prior to study 
(apart from RU asked 
to refrain from CBS 
only for 24h prior to 
study visits) 
✓ Non-
parametric 
mixed 
model 
✓ 
D’Souza et 
al.,2009 
✓/✕Double-
blind; not 
randomized or 
counterbalanced 
✓1. RU, lifetime 
CBS use > 50 
times, last use 
within past week 
(CBS in urine), 
recent use ≥ 10 in 
past month, CUD 
DSM-IV criteria; 
2. NRU, lifetime 
CBS use from < 5 
to > 100 times, no 
use in past week 
(no CBS in urine), 
no CUD DSM-IV 
criteria  
✓ 
18-55 
(range) 
✓ Male (n 
= 20), 
Female (n = 
3) 
✓ 2 ml IV ∆9-
THC (0.0286 
mg/kg)  in 95% 
ethanol 
solution 
✓1 single IV 
admin. of ∆9-THC 
over 20 min   
✓ Matched for 
demographic 
characteristics 
(age, IQ, race, 
weight); years of 
education, RU < 
NRU; female 
participants only 
in NRU, however 
reanalysis 
excluding these 
subjects did not 
change results 
 
✓ ✓Exclusion criterion 
(by  DSM psychiatric 
interview for Axis I 
disorders + no family 
history of DSM Axis I 
disorder; and a general, 
physical, and 
neurological 
examination, ECG, and 
laboratory tests) 
✓ Exclusion criterion 
for alcohol and other 
substance use disorders 
but not nicotine 
dependence, however 
only 1 current tobacco 
smoker (RU, ≥ 5 cig. 
per day); asked to 
refrain from alcohol 
and substances for 2 
weeks prior to study 
(apart from RU asked 
to refrain from CBS 
only for 24h prior to 
study visits) 
✓ Non-
parametric/ 
linear  
mixed 
model, 
Bonferroni 
correction 
✓ 
Ramaekers et 
al., 2009 
✓Double-blind, 
randomized, 
balanced, two-
way mixed 
model 
✓1. RU, CBS use 
over previous year 
≥ 4 per week 
(CBS in urine); 2. 
NRU, CBS use 
over previous year  
✓ 
1. RU, 
23.2±3.3; 
2. NRU, 
22.8±2.3 
(M±SD) 
✓ Male (n 
= 17), 
Female (n = 
7) 
✓500 μg/kg 
∆9-THC (13%) 
per MJ cig. 
✓10-min of MJ 
smk.  
✓ Matched for 
demographic 
characteristics 
(age, gender, 
weight) 
✓ ✓Exclusion criterion 
(by medical 
examination and 
laboratory analyses); no 
endocrine, psychiatric, 
and neurological 
✓Exclusion criterion 
for substance abuse  
history (by 
questionnaires), 
excessive drinking (>25 
standard alcoholic 
✓
ANOVA, 
Binomial 
tests 
✓ 
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≤ weekly (no CBS 
in urine) 
condition; normal 
weight and BMI; no 
hypertension; no non-
cig. smk. 
consumptions per 
week); asked to refrain 
from alcohol on study 
day and from 
substances during all 
study (by UDS) 
Ranganathan 
et al., 2009 
✓/✕Double-
blind for both 
studies, 
randomized and 
counterbalanced 
only for 1 study 
✓ 1. RU, lifetime 
CBS use > 50 
times, last use 
within past week 
(CBS in urine), 
recent use ≥ 10 in 
past month, CUD 
DSM-IV criteria; 
2. NRU, lifetime 
CBS use from < 5 
to > 100 times, no 
use in past week 
(no CBS in urine), 
no CUD DSM-IV 
criteria   
✓ 
18-55 
(range); 
1. RU, 
28.3±10; 
2. NRU, 
24.6±5 
(M±SD) 
✓ Male (n 
= 57), 
Female (n = 
19) 
✓ 2 ml IV ∆9-
THC (Study I: 
0.0357 or 
0.0714 mg/kg; 
Study II: 
0.0286 mg/kg) 
in 95% ethanol 
solution 
✓1 single IV 
admin. of ∆9-THC 
✓/✕ Matched 
for some 
demographic 
characteristics 
(gender, 
education, 
socioeconomic 
status, 
contraception); 
not for age 
✓ ✓Exclusion criterion 
(by DSM psychiatric 
interview for Axis I 
disorders + no family 
history of DSM Axis I 
disorder; and a general, 
physical, and 
neurological 
examination, ECG, and 
laboratory tests) 
✓ Exclusion criterion 
for alcohol and other 
substance use disorders 
but not nicotine 
dependence, however 
matched for smk. status 
and other substances/ 
alcohol use; asked to 
refrain from alcohol 
and substances for 2 
weeks prior to study 
(apart from RU asked 
to refrain from CBS 
only for 24h before the 
study visits) 
✓ Linear 
mixed 
model, 
Tukey’s 
multiple 
comparison 
✓ 
Bedi et al., 
2010 
✓/✕Double-
blind, 
counterbalanced, 
within subject; 
not randomized 
✓ RU, CBS use 
≥ 2 per week  
✓ 
21-50 
(range), 
36.6±1.3 
(M±SEM
) 
✓ Male ✓ 20-40 mg of 
Dronabinol per 
caps. 
✓ 16-day drug 
period of 
Dronabinol caps. 
admin. (5 mg qid 
for 2 days, then 10 
mg qid) 
NA ✓ ✓Exclusion criterion 
(by medical and 
psychiatric evaluation, 
ECG, and laboratory 
analyses) 
✓/✕ Exclusion 
criterion for substance 
use disorders but not 
nicotine dependence 
✓ 
ANOVA 
✓ 
Böcker et al., 
2010 
✓ Double-
blind, 
randomized, 
four way, cross-
over  
✓ CBS use, 
range: 2-18 cig. 
per month 
(median: 8), 
duration of use: 
2–18 years 
(median: 6.5) 
✓ 
18-33 
(range) 
✓ Male ✓ 29.3, 49.2 
mg, or 69.4 mg 
∆9-THC per 
MJ cig. 
✓ 4-day drug 
period of smk. 1 
∆9-THC cig. per 
day (inhalation 
cycle over 22 min: 
getting ready, 3 s; 
inhalation, 2 s; 
breath-holding, 3 s; 
exhalation and rest, 
32 s) 
✕ however age 
did not change 
results 
✓ ✓Exclusion criterion 
(by medical health 
questionnaire); no one 
was on any medication 
from 15 days before 
until the end of the 
study 
✓ Exclusion criterion 
for substance use; 
asked to refrain from 
alcohol and drug intake 
for at least 10h prior to 
study (by staying in 
hospital overnight and 
UDS); alcohol and 
tobacco use did not 
change results 
✓ 
MANOVA 
✓ 
Barkus et al., 
2011 
✓ Double-
blind, 
randomized, 
counterbalanced, 
repeated 
measures 
✓ lifetime CBS 
use: 153±324 
times (M±SD), 
range: 1-1000; last 
use: 43 weeks 
ago, range: 2-288 
✓ 
26.3±4.2 
(M±SD) 
✓ Male ✓ 5 ml IV ∆9-
THC (2.5 mg) 
in 2.5% ethanol 
solution 
✓1 single IV 
admin. of ∆9-THC, 
1ml/min 
NA ✓ ✓Exclusion criterion 
(by General Health 
Questionnaire); no 
mental illness + no 
family history of mental 
illness, no ongoing or 
serious past physical 
illness 
✓/✕ Exclusion 
criterion for substance 
use disorders but not 
nicotine dependence 
(by MAST and DAST); 
asked to refrain from 
alcohol and drugs for 
24h prior to study (by 
UDS) 
✓ 
Friedman’s 
test, 
Wilcoxon’s 
test, 
Spearman’s 
correlation   
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Bosker et al., 
2012 
✓ Double-
blind, 
randomized,  
balanced, three 
way, cross-over  
✓ 1. RU, daily 
CBS use or nearly 
so (range: 7.7-
23.1 joints per 
week), lifetime 
CBS use: 
2442.2±708.8 
times (M±SD), 
pattern of use > 
160 times per year 
(CBS in urine); 2. 
NRU, lifetime 
CBS use: 
274.1±89.6 times 
(M±SD), pattern 
of use range: 5-36 
times per year (no 
CBS in urine) 
✓ 
23.6±0.6 
(M±SD) 
✓ Male (n 
= 14), 
Female (n = 
10) 
✓ 10-20 mg of 
Dronabinol per 
caps. 
✓2 single admin. 
of dronabinol caps., 
at least 4 days apart 
✓/✕ Matched 
for gender; not 
for other 
demographic 
characteristics 
✓ ✓Exclusion criterion; 
all free from 
psychotropic 
medication and in good 
physical health, no 
major medical 
condition, 
cardiovascular 
abnormalities, 
hypertension, or past/ 
current psychiatric 
disorder 
✓/✕ Exclusion 
criterion for substance 
abuse or addiction to 
non-cannabinoids and 
excessive drinking; 
asked to refrain from 
alcohol and caffeine for 
24h prior to study (by 
ABT and UDS);  
tobacco used not 
assessed 
✓ 
ANOVA, 
Chi-Square, 
Spearman’s 
correlation 
✓ 
D’Souza et 
al.,2012 
✓ Double-
blind, 
randomized, 
counterbalanced, 
cross-over 
✓/✕ lifetime 
CBS use from < 
10 to > 1000 
times, last use: 
415.02 days ago 
(range: 1-3650), 
recent use range: 
0-29 days in past 
month, pattern of 
use from 1 per 
year to 7 per 
week; 1. RECU, 
CBS use in last 30 
days; 2. NRECU, 
no CBS use in last 
30 days    
✓ 
18-35 
(range), 
25.9±7.8 
(M±SD) 
✓ Male (n 
= 17), 
Female (n = 
9) 
✓ IV ∆9-THC 
(0.015 or 0.03 
mg/kg) in 
ethanol 
solution 
✓1 single IV 
admin. of ∆9-THC 
on 2 occasions, at 2 
different doses, and 
over 10 min, at least 
3 days apart 
✕ ✓ ✓Exclusion criterion 
(by DSM psychiatric 
interview for Axis I 
disorders + no family 
history of DSM Axis I 
disorder; and a general, 
physical, and 
neurological 
examination, ECG, and 
laboratory tests) 
✓ Exclusion criterion 
for substance use 
disorders but not 
nicotine dependence, 
however, tobacco use ≤ 
10 per day, asked to 
refrain from alcohol, 
caffeine, and 
substances for 2 weeks 
prior to study, apart 
from RU asked to 
refrain from CBS only 
for 24h prior to study 
visits (by UDS) 
✓ 
ANOVA, t-
test, non-
parametric 
mixed 
model 
✓ 
Theunissen et 
al., 2012 
✓ Double-
blind, 
randomized,  
balanced, two 
way, cross-over  
✓1. RU, CBS use 
> 4 times per 
week, pattern of 
use: 340±86 
(M±SD) per year 
(CBS in urine); 2. 
NRU, CBS use < 
2 times per week,  
pattern of use: 
55±36 (M±SD) 
per year (no CBS 
in urine) 
✓ 
1. RU, 
23.2±3.3; 
2. NRU, 
22.8±2.3 
(M±SD) 
✓ Male (n 
= 17), 
Female (n = 
7) 
✓500 μg/kg 
∆9-THC (13%) 
per MJ cig. (0.8 
g) 
✓10-15-min of MJ 
smk. (RU, 0.256 g; 
NRU, 0.277 g) 
✓ Matched for 
demographic 
characteristics 
(age, gender, and 
weight) 
✓ ✓Exclusion criterion 
(by medical screening 
and laboratory tests); all 
free from psychotropic 
medication and in good 
physical health; no  
major medical, 
endocrine, and 
neurological condition,  
hypertension, color 
blindness, dyslexia, or 
past/ current psychiatric 
✓Exclusion criterion 
for substance abuse or 
addiction to non-
cannabinoids, excessive 
drinking (> 20 
consumptions per 
week), excessive smk. 
(> 25 cig. per day); 
asked to refrain from 
alcohol for 24h prior to 
study, caffeine on study 
day, and substances 
✓ 
ANOVA, 
Pearson 
correlation 
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disorder     during all study (except 
CBS, only NRU asked 
to refrain for at least 5 
days prior to study) (by 
ABT and UDS) 
Fabritius et 
al., 2013 
✓/✕ Cross-
over; not 
double-blind, 
counterbalanced 
or randomized 
✓1. RU, CBS use 
≥ 10 joints per 
month (2.3 joint 
per week) in last 3 
months (CBS in 
urine); 2. NRU, 
CBS use ≥ 1 joint 
per month but ≤ 1 
joint per week in 
last 3 months 
✓ 
18-30 
(range); 
1. RU, 
22.7+2.4 
(M+SD); 
2. NRU, 
23.9+3 
(M+SD) 
✓ Male ✓11% ∆9-
THC and < 1% 
CBD per MJ 
cig.  
 
✓1 single admin. 
of 1 MJ cig. 
(inhalation cycle: 
getting ready and 
start signal, 3 s; 
inhalation, 2 s; 
breath-holding, 5 s; 
exhalation and rest, 
50 s. Sequence 
repeated until 2/3 of 
the joint was 
consumed) 
 
✓ Matched for 
demographic 
characteristics 
(age and 
ethnicity) 
✓ ✓Exclusion criterion 
(by structured interview 
conducted by a 
medical staff) 
✓/✕Exclusion 
criterion for substance 
use; alcohol and 
tobacco use not 
assessed  
✓  
Mann–
Whitney U 
test 
✓ 
Gorelick et 
al., 2013 
✕ ✓RU, lifetime 
CBS use > 1000 
times, daily 
pattern of use in 
past 3 months 
(5.5±5.9 joints per 
day, M±SD; 
range: 1-24), last 
use within 24 h 
(CBS in urine) 
✓ 
18-45 
(range), 
24.6+3.7 
(M±SD) 
✓ Male ✓ 20 mg of 
Dronabinol per 
caps. 
✓ 6-day drug 
period of 
Dronabinol caps. 
admin. every 3.5-6 
h (day 1: 40 mg, 
day 2-4: 100 mg; 
day 5-6: 150 mg) 
NA ✕ ✓Exclusion criterion; 
no past/ present 
significant medical 
disease, no history of 
psychosis, no current 
DSM-IV Axis I 
disorder, normal cardiac 
function, IQ > 85, no 
previous adverse events 
related to CBS 
✓/✕Exclusion 
criterion for substance 
use disorders (by UDS) 
but not nicotine or 
caffeine dependence, ≥ 
6 alcohol drinks/day ≥4 
times/week in 
the month before study; 
9 daily tobacco users 
(17.9±18.8 cig. per 
day), others past users 
✓ 
ANOVA, 
Greenhouse
-Geisser 
correction 
✓ 
Sewell et al., 
2013 
✓ Double-
blind, 
randomized, 
counterbalanced 
✓/✕ 1. RECU, 
CBS ≥ 8 times in 
last 30 days; 2. 
NRECU, CBS ≤ 2 
per week in last 
30 days 
✓ 
18-35 
(range); 
1. RECU, 
20.7+1.4 
(M+SD); 
2. 
NRECU, 
23.1+3.6 
✓ Male (n 
= 33), 
Female (n = 
11) 
✓ IV ∆9-THC 
(0.015 to 0.05 
mg/kg) in 
ethanol 
solution 
✓1 or 2 single IV 
admin. of ∆9-THC, 
at 3 different dose 
ranges, and at least 
3 days apart 
✓/✕ Matched 
for some 
demographic 
characteristics 
(gender, 
education, 
ethnicity, BMI, 
IQ, handedness); 
not for age 
(RECU < 
NRECU) 
✓ ✓Exclusion criterion 
(by DSM psychiatric 
interview for Axis I 
disorders and a general, 
physical, and 
neurological 
examination, ECG, and 
laboratory tests) 
✓ Exclusion criterion 
for substance use 
disorders, asked to 
refrain from alcohol 
and substances for at 
least 1 week prior to 
study (for NRU by 
UDS), and matched for 
smk. status 
✓ 
ANOVA, t-
test,  Chi-
Square/ 
Fisher’s 
test, 
Cohen’s d, 
linear 
mixed 
model 
✓ 
Vandrey et 
al., 2013 
✓/✕ 
Counterbalanced
, within-
subjects, cross-
over; not 
randomized 
✓RU, pattern of 
CBS use: 25 days 
per month in past 
3 months, 4+2 
times (M±SD) per 
day (CBS in 
✓ 
18-55 
(range), 
34+9 
(M±SD) 
✓ Male (n 
= 12), 
Female (n = 
1) 
✓ 10, 20, 40 
mg of 
Dronabinol per 
caps. 
✓ 51-day drug 
period of 
Dronabinol caps. 
admin. (10, 20,or 
40 mg tid) followed 
by a single CBS 
NA ✓ ✓Exclusion criterion 
(by DSM-IV-TR 
psychiatric interview 
for Axis I disorder and 
ECG); all free from 
psychotropic 
✓/✕ Exclusion 
criterion for substance 
use disorders but not 
nicotine dependence; 
no acute drug or 
alcohol intoxication 
✓ 
Regression, 
Student-
Newman-
Kuels 
multiple 
✓ 
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urine), 11 subjects 
with CBS 
dependence 
exposure (5.7% ∆9-
THC, 0.8 g, 5 puffs) 
medication; no history 
of seizures, severe 
hepatic impairment, or 
conditions associated 
with cognitive 
impairment 
apart from CBS (by 
ABT and UDS) 
comparison 
test, 
correlation 
Cortes-
Briones et al., 
2015 
✓ Double-
blind, 
randomized, 
counterbalanced, 
cross-over 
✓/✕ lifetime 
CBS use from ≤ 5 
to > 1000 days, 
last use: 402.72 
days ago (range: 
1-3650), recent 
use range: 1-29 
days in past 
month, pattern of 
use from 1 per 
year to 7 per 
week; 1. RECU, 
CBS use in last 30 
days; 2. NRECU, 
no CBS use in last 
30 days 
✓ 
18-35 
(range), 
25.7±7.6 
(M±SD) 
✓ Male (n 
= 14), 
Female (n = 
6) 
✓ IV ∆9-THC 
(0.015 or 0.03 
mg/kg) in 
ethanol 
solution 
✓1 single IV 
admin. of ∆9-THC 
on 2 occasions, at 2 
different doses, and 
over 10 min, at least 
3 days apart 
✕ ✓ ✓Exclusion criterion 
(by  DSM psychiatric 
interview for Axis I 
disorders + no family 
history of DSM Axis I 
disorder; and a general, 
physical, and 
neurological 
examination, ECG, and 
laboratory tests) 
✓ Exclusion criterion 
for substance use 
disorders but not 
nicotine dependence, 
however, tobacco use ≤ 
10 per day; asked to 
refrain from alcohol, 
caffeine, and 
substances for 2 weeks 
prior to study, apart 
from RU asked to 
refrain from CBS only 
for 24h prior to study 
visits (by UDS) 
✓
Generalized 
estimating 
equations, 
Holm–
Bonferroni 
sequential 
procedure  
✓ 
Desrosiers et 
al., 2015 
✕ ✓1. RU, CBS use 
≥ 4 times per 
week in past 3 
months (CBS in 
urine); 2. NRU, 
CBS use < 2 times 
per week in past 3 
months 
✓ 
18-45 
(range); 
1. RU, 
25.7±4.6; 
2. NRU, 
31.4±6.3 
(M±SD) 
✓ Male (n 
= 18), 
Female (n = 
7) 
✓54 mg ∆9-
THC 
(6.8±0.2%) per 
MJ cig. 
✓10-min of MJ 
smk. 
✓/✕ Matched 
for some 
demographic 
characteristics 
(gender, BMI); 
not for age and 
race/ ethnicity 
✕ ✓/✕ Exclusion 
criterion; no medical 
condition, history of 
neurological illness, 
hypertension, 
tachycardia; psychiatric 
comorbidity not 
assessed 
✕ ✓ 
ANOVA, t-
test, 
Hunyh-
Feldt 
correction 
✓ 
Farris et al., 
2016 
✓/✕Double-
blind, 
counterbalanced, 
within-subjects; 
not randomized 
✓ CBS use ≥ 2 
days per week in 
past month, and ≥ 
weekly in past 6 
months (2.1±1.2 
times per day, 
M±SD); CBS 
dependence: 
13.6%, CBS 
abuse: 29.5%; 1. 
RU, CBS use on 
94.4% of days (~ 
6.6 days per 
week); 2. NRU, 
CBS use on 
50.0% of days 
✓ 
18-44 
(range), 
21.5±4.5 
(M±SD) 
✓ Male (n 
= 58), 
Female (n = 
30) 
✓ 2.8-3.0% 
∆9-THC per 
MJ cig. 
✓smk. 1 MJ cig. ✕ ✓ ✓Exclusion criterion 
(by  DSM psychiatric 
interview for Axis I 
disorders and physical 
exam for 
contraindicated medical 
issues); no BMI > 30 
✓ Exclusion criterion 
for substance use (by 
UDS) and tobacco use 
≥ 20 cig. per day 
(46.6% smokers, 
4.2±3.8 cig. per day on 
smk. days); 29.5 % 
alcohol users (4.2±2.4 
drinks per drinking 
day); asked to refrain 
from alcohol for 24h, 
caffeine for 1h, and 
CBS and tobacco for 
15h prior to study (by 
ACMT and ABT) 
✓t-test, 
refression 
✓ 
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RU, regular users; CBS, CBS; NRU, non-regular users; IU, intermittent users; M, mean; SD, standard deviation; L, light; LM, low moderate; HM, high moderate; H, heavy; NU, non-users; CUD, CBS use disorder; DSM, Diagnostic and Statistical Manual of 
Mental Disorders; RECU, recent users; NRECU non recent users; mg, milligrams; Δ9-THC, Delta-9-tetrahydrocannabinol; MJ, marijuana; CBN, cannabinol; CBD, Cannabidiol; ml, milliliter; IV, intravenous; kg, kilogram; μg, micrograms; g, grams; h, hour; 
smoking, smk.; NS, not significant; cigarette(s), cig.; capsule(s), caps.(s); po., per os; min, minute(s); administration(s), admin.; qid, four times per day; tid, three times per day; vap., vaporized; WAIS, Wechsler Adult Intelligence Scale; IQ, Intelligence 
quotient; NA, not applicable; UDS, urine drug screen; ECG, electrocardiogram; EEG, electroencephalogram; MMPI, Minnesota Multiphasic Personality Inventories; SCL-90, Symptom Checklist-90; BMI, body mass index; MAST, Michigan Alcohol 
Screening Test; DAST, Drug Abuse Screening Test; ABT, Alcohol Breath Test; ACMT, Alveolar Carbon Monoxide Test; MDMA, 3,4-Methylenedioxymethamphetamine; LSD, Lysergic acid diethylamide; DMT, N,N-Dimethyltryptamine; ANOVA, 
analysis of variance; MANOVA, multivariate analysis of variance 
Ramaekers et 
al., 2016 
✓ Double-
blind, 
randomized, 
counterbalanced, 
three way, cross-
over 
✓ CBS use ≥ 2 
times in past 3 
months, recent 
use: 44.8 times in 
past 3 months 
(range: 2-100; 
clustered in 1. L 
use, 1-24 times; 2. 
LM use, 25-49 
times; HM use, 
50-74 times; H 
use, 75-100 times)   
✓ 
18-39 
(range), 
22.8 (M) 
✓ Male (n 
= 96), 
Female (n = 
26) out of 
original 
cohort of 
132 
✓300 μg/kg 
∆9-THC (11-
12%) vaporized 
CBS 
✓ vap. dose over 2-
3 min  
✕ However 
study participants 
evaluated as a 
whole group 
✓ ✓Exclusion criterion 
(by medical 
examination, laboratory 
analyses, and ECG); all  
free from psychotropic 
medication and in good 
physical and mental 
health, normal weight 
(BMI, 18-28), no 
cardiovascular 
abnormalities, 
hypertension, or past/ 
current psychiatric or 
neurological disorder 
✓/✕ Exclusion 
criterion for cocaine 
dependence, excessive 
alcohol use (> 20 units 
per week) or smk. (> 15 
cig. per day); use of 
MDMA (88%), 
amphetamines (73%), 
mushrooms (61%), 
LSD (20%), and other 
drugs (60%, nitrous 
oxide, DMT, and 
ketamine); asked to 
refrain from drug and 
alcohol use (by ABT 
and UDS) 
✓ 
ANOVA, 
Pearson 
correlation 
✓ 
Newmeyer et 
al., 2017a 
✓ Double-
blind, 
randomized, 
double-dummy, 
cross-over 
✓1. RU, CBS use 
≥ 5 times per 
week in past 3 
months (CBS in 
urine); 2. NRU, 
CBS use ≥ 2 times 
per month but < 3 
times per week in 
past 3 months (no 
CBS in urine) 
✓ 
18-46 
(range) 
✓ Male (n 
= 15), 
Female (n = 
5) 
✓1. 
0.734±0.05 g 
∆9-THC 
(6.9±0.95%) 
per MJ cig.; 2. 
CBS-
containing 
brownie; 3. 
Vaporized CBS 
✓po., smk., or vap. 
dose ad libitum 
over 10 min 
✓/✕ Matched 
for some 
demographic 
characteristics 
(age, gender, 
BMI); not for 
race/ ethnicity 
✓ ✓Exclusion criterion 
(by medical and 
psychological 
evaluation) 
✕, tobacco use allowed 
while on the research 
unit 
✓ t-test, 
ANOVA, 
planned 
Helmert 
contrasts, 
Bonferroni 
correction 
✓ 
Newmeyer et 
al., 2017b 
✓ Double-
blind, 
randomized, 
double-dummy, 
cross-over 
✓1. RU, CBS use 
≥ 5 times per 
week in past 3 
months (CBS in 
urine); 2. NRU, 
CBS use ≥ 2 times 
per month but < 3 
times per week in 
past 3 months (no 
CBS in urine) 
✓ 
18-46 
(range) 
✓ Male (n 
= 15), 
Female (n = 
5) 
✓1. 
0.734±0.05 g 
∆9-THC 
(6.9±0.95%) 
per MJ cig.; 2. 
CBS-
containing 
brownie; 3. 
Vaporized CBS 
✓po., smk., or vap. 
dose ad libitum 
over 10 min 
✓/✕ Matched 
for some 
demographic 
characteristics 
(age, gender, 
BMI); not for 
race/ ethnicity 
✓ ✓Exclusion criterion 
(by medical and 
psychological 
evaluation) 
✓/✕ Exclusion 
criterion for substance, 
caffeine, or nicotine 
dependence 
✓ t-test, 
ANOVA, 
Greenhouse
–Geisser 
correction   
✓ 
AC
EP
TE
D M
AN
US
CR
IPT
66 
 
Table 3. Summary of the effects of cannabis on development of tolerance in man 
Domain Number of 
subjects 
per study            
(M ± SD) 
Total 
number of 
subjects              
(n) 
Evidence 
Intoxication and subjective effects 28.6 ± 24.5 629 15 +; 7 - 
Cardiac parameters 
 
Increase in heart rate 
Hypotension 
 
 
23.5 ± 13.3 
26.1 ± 14.3 
 
 
376 
183 
 
 
11 +; 5 - 
3 +; 4 - 
Cognition 
 
Memory and learning 
Attention 
Psychomotor ability 
Impulsivity 
Time perception 
 
 
23.6 ± 14.2 
30 ± 33 
31.6 ± 34.3 
57 ± 56.3 
 
 
189 
330 
316 
171 
44 
 
 
6 +; 2 - 
7 +; 4 - 
6 +; 4 - 
3 – 
+ 
Psychopathological symptoms 
 
Psychotomimetic symptoms 
Perceptual alterations 
Mood changes 
Anxiety 
Confusion 
 
 
27.5 ± 17.9 
33.7 ± 15.9 
24 ± 25.2 
38.5 ± 19.1 
33.5 ± 20.6 
 
 
110 
101 
72 
77 
67 
 
 
4 + 
3 + 
1+; 2 - 
2 + 
2 + 
Cannabinoid levels 39.4 ± 32.1 473 8 +; 4 - 
EEG signals 29.2 ± 13.5 146 5 + 
Other behavioral measures 
 
Driving skills 
Sleep quality 
Weight 
 
 
22 ± 2.8 
24 ± 25.2 
30 ± 32.5 
 
 
44 
72 
60 
 
 
2 + 
2 +; 1 -  
2 -  
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EEG, electroencephalogram; BDNF, brain-derived neurotrophic factor; CO, carbon monoxide; ‘+’ refers to positive evidence of tolerance; ‘-‘ 
refers to negative evidence of tolerance 
Food-related behavior 
Social behavior 
10.3 ± 2.9 
9.5 ± 3.5 
31 
19 
1 +; 2 -  
2 -  
Other physiological measures 
 
Cortisol 
Prolactin 
BDNF 
Dopamine release 
Breath holding 
Respiration rate/ CO 
Other body response 
 
 
64 ± 17 
44.75 ± 24.3 
 
 
 
128 
179 
23 
9 
88 
20 
53 
 
 
2 + 
3 +; 1 -  
+ 
- 
+ 
- 
+ 
AC
CE
PT
ED
 M
AN
US
CR
IPT
